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Abstract 
 
In New Zealand there are currently no regular external audits to verify the full 
treatment chain in radiotherapy. This thesis reports on a project to devise such an 
audit procedure suitable to assess the accuracy of the delivery of prescribed 
radiotherapy doses to patients over the full treatment process. The National Radiation 
Laboratory (NRL), regulatory authority, will use the method developed to conduct 
biennial audits of all radiotherapy centres. 
 
A commercial chest phantom with a MOSFET dosimetry system was provided for this 
project. The MOSFETs were commissioned and their characteristics determined, 
namely reproducibility, energy dependence and angular dependence. The MOSFETs 
were also tested in a clinical environment with the phantom. Measurements were 
carried out to test the MOSFET capabilities in both lung and soft tissue in the 
phantom. Two plans were devised for the audit process, a straightforward one with 
two parallel opposed beams and a more complex one involving lung tissue and 
wedges. These plans were designed to test the entire treatment planning and delivery 
process. 
 
It was found that each MOSFET detector needed to be individually calibrated. 
Reproducibility was found to have an average standard deviation of 2% on standard 
sensitivity and 1.2% on high sensitivity. The angular dependence of the detectors 
showed that when the MOSFET was rotated by 90 degrees to the beam axis a drop in 
response of 3% was observed with 6 MV. The energy dependence factor was 
constant within uncertainty for all MOSFETs.  
 
Overall, the MOSFET and phantom dosimetry system was determined to be suitable 
for the audit. The measurements with phantom showed that doses in high dose 
regions could be determined accurately.  The greatest variation from the Treatment 
Planning system dose to the measured dose was 6%. The trial runs of the audit in two 
New Zealand radiotherapy centres showed that the procedure created is able to find 
discrepancies within the desired 5%, recommended by the ICRU, in the prescribed 
dose to the phantom. 
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1. Introduction  
 
Cancer in New Zealand 
In New Zealand, as of 2003, cancer was the leading cause of death, overtaking heart 
disease [1].  In the same year it accounted for 28.6% of all deaths [1].  In the older 
age groups cancer occurs at a much higher rate.  In the over 75 age group, the rate of 
cancer is nearly four times higher than in the 45-64 age group [1]. The rate of new 
registrations of cancer is also increasing; between the period of 1995 and 2003, an 
increase of 17.2% new cases were registered as is shown in Figure 1.1. As the 
average age of the population increases, the rate of cancer is also predicted to 
increase [1].  It then follows that the treatment of cancer will become increasingly 
important. 
 
 
Figure 1.1  The total number of cancer registrations by sex from 1995 to 2004 [1].  
A variety of treatment options exist.  The common treatments are surgery, 
chemotherapy and radiotherapy and sometimes a combination of these.  Of the 
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17,000 people newly diagnosed with cancer every year, about 40% (6800) are given 
radiotherapy treatment [1].  Radiotherapy is used both as a palliative (to relieve 
symptoms) and curative treatment. 
 
Radiotherapy works by delivering ionising radiation to the tumour volume.  The 
common modalities in New Zealand are photons and electrons [2].  Linear 
accelerators (linacs) usually deliver the dose and are capable of delivering both 
electrons and photons.  This method of treatment works by damaging the DNA in the 
cancer cells thus preventing them from reproducing [3].  It is vitally important that the 
cells in healthy tissue receive minimal damage while the cancer cells receive a 
sufficient amount to control the cancerous tissue [4].  Small changes in dose can have 
large effects on patient outcome.  Too little means that the cancer is not sufficiently 
controlled and too much may lead to side affects and permanently damage healthy 
tissue [5].  For example, an increased dose to the skin can cause deterministic effects 
such as erythema and necrosis; while too much to the spinal cord can cause 
irreparable paralysis.  Much importance in radiotherapy is therefore placed on 
accurately delivering the correct dose of ionising radiation to a precise location in the 
patient [4]. 
 
In clinical practice great care is taken to ensure that the administered dose matches 
the prescribed one.  If the discrepancy between these two doses becomes too large a 
radiation accident has occurred.  The International Atomic Energy Agency (IAEA) 
records these accidents so that other centres around the world may learn from 
previous mistakes [6, 7].  The IAEA definition of a radiation accident is defined as 
follows: 
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• “Accident refers to any unintended event, including operating errors, equipment 
failures or other mishaps, the consequences or potential consequences of which 
are not negligible from the point of view of protection or safety.” 
 
There are currently six radiotherapy treatment centres in New Zealand (all in public 
hospitals), with a further two private centres planned for 2009.  The current six New 
Zealand centres are in Auckland, Hamilton, Palmerston North, Wellington, 
Christchurch and Dunedin.  The two private centres are planned for Auckland and 
Christchurch.  With nearly 7000 patients to treat every year [1], these facilities are 
very busy and are running close to capacity.  
 
Planning and delivering a radiotherapy treatment is a complex process and consists of 
multiple steps that are typically carried out by different hospital staff.  Typically the 
process of radiotherapy is as follows: the patient is imaged using a CT scanner where 
tattooed set-up marks are applied to the patient to allow accurate positioning to 
receive the treatment, the data is transferred to the treatment planning system, where 
the Radiation Therapist (RT) makes a treatment plan based on the contouring of the 
tumour and the organs at risk by an oncologist, the plan is checked by a medical 
physicist, which is then sent through a verification system, and then finally the 
treatment using a linear accelerator (linac), takes place.  
 
In each step of the treatment chain outlined above can introduce potential errors that 
may affect the success of the treatment.  Section 1.1 outlines these potential sources 
of error. 
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1.1. Potential sources of error in radiotherapy 
There are several potential sources of error in the treatment chain which could affect 
the radiation dose that the patient receives [8].  The following is a brief overview of the 
sources of potential errors.  
 
Treatment Planning Systems 
The Treatment Planning Systems (TPS) calculates the dose in any place within a 
patient given a set of specified beam parameters.  All of these TPSs account for 
differences in tissue density and volume along with machine specific output data to 
calculate the required dose.  It is critically important that the CT data of patient density 
is correct so that the treatment planning system has the correct information to 
calculate the dose properly and also that the CT data are accurately converted to 
electron density data in the TPS.  In New Zealand the TPSs that are used are 
Pinnacle (Koninklijke Philips Electronics, Bothell, USA), Eclipse (Varian Medical 
Systems, Palo Alto, USA) and XIO (CMS, St Louis, USA).  The algorithms used for 
dose calculations differ between TPSs, further detail is given in one of the sections 
below.   
 
CT number and electron density conversions 
CT scans represent the different tissues within a patient by means of Hounsfield 
numbers (HU1) [4].  For the TPS to correct for tissue inhomogeneities the HU need to 
be converted into electron densities.  This is accomplished by means of a CT to 
electron density conversion table. Since the treatment planning algorithms that 
calculate the dose depend on the electron densities, it is important that these electron 
densities are accurate as inaccurate electron densities can lead to an inaccuracy of 
                                                 
1
 X-ray attenuation unit used in CT Scan interpretation which characterises the relative density 
of the patient. The radio-density of distilled water at standard pressure and water is defined as 
zero HU, while air is defined as -1000 HU. 
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the delivered dose to the patient [9].  A CT number to electron density conversion 
table has to be determined by the medical physicists as each CT scanner can give 
slightly differing conversions.  The information from the scan is then entered into the 
TPS.  If this is carried out incorrectly, it could affect patient dose. 
 
Treatment planning algorithms 
In treatment planning, compromises may be made between speed and accuracy [10].  
The most accurate algorithms such as Monte Carlo [11, 12] take longer for the system 
to calculate.  In clinical practice, however, Radiation Therapists (RTs) have many 
patients to design plans for so the use of faster and less accurate algorithms are 
necessary.  Some algorithms, for example, may underestimate the dose distributed by 
scatter outside of the main beams.  Algorithms tend to be the least accurate where 
there are boundaries of sharp density changes [13] such as lung tissue interfaces in 
the lung.  When a new TPS is commissioned and installed, the linac geometry and 
output is modelled by medical physicists and from then on only consistency checks 
are performed, so if the system was commissioned incorrectly at the start, the error 
might not be realised in later checks.  In addition to errors associated with incorrectly 
commissioning a commercial TPS, a major potential source of error arises when the 
TPS software is upgraded.  This can give rise to changes to the TPS algorithms or 
stored machine beam data.  Some algorithms include; the anisotropic analytical 
algorithm, the collapsed cone, the multi-grid superposition, fast Fourier transform 
convolution, and Monte Carlo simulations [14].  Different centres around New Zealand 
use different TPSs and, therefore, different algorithms.   
 
Machine output  
Commissioning a new linac provides the baseline values for the operation of the linac 
and the data for the TPS.  Daily measurements as well as routine quality assurance 
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(QA) checks by the medical physicists determined by means of measurement verify 
that the machine output factors are within certain margins of the original machine 
calibration. Therefore if the original calibrations were incorrect, their daily 
measurements will also be flawed.  The linac output measurements are audited every 
two years by the National Radiation Laboratory (NRL) and each centre’s ionisation 
chambers are calibrated every other year (also usually by the NRL).  Therefore major 
discrepancies between prescribed and delivered dose are unlikely to occur from this 
source, though they are not unheard of.  In Canada in 1985-1987, six known 
accidental exposures occurred by the same type of linac [5].  Under specific 
circumstances when the linac went from x-ray mode to electron mode, the linac 
operated without the x-ray target and beam flattener which then lead to massive 
overdoses, causing the deaths of three patients.  This continued for this period of time 
as there was no efficient mechanism to follow up reports of suspected accidents [5].  
This was machine failure of a type that would not be picked up in daily measurements 
due to the specific circumstances in which the overdoses occurred. 
 
Human error 
Human error is one of the main sources of radiation accidents in radiotherapy [15].  
This section overlaps with the other section in the potential sources of error section as 
they all have the capacity for human error to be the main factor.  For example in 
Glasgow in 2006 [16] a patient received a 60% overdose due to a radiotherapy 
accident after a member of staff incorrectly transcribed a number.  In a radiotherapy 
centre in the UK from 1986-1987 the Co 60 calibrations were based on incorrect 
tables and there was no independent check of the dose rate, with the result being that 
207 patients were given a 25% overdose [6].  In the years 1982-1991, again in the 
UK, a treatment planning system was commissioned inappropriately which caused 
nearly 1000 patients to be under dosed by 5-30% [6].  In a more serious incident in 
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Spain, which resulted in at least 18 deaths from radiation, there was an error in the 
maintenance of a linac and procedures regarding the linac being taken to and from 
maintenance were not followed.  The physicists at this centre were not informed of 
any maintenance taking place.  The procedures for regular machined output 
verifications were not performed and the display signals were ignored [5, 6].  This is a 
particularly good example of the importance of communication in radiotherapy [5].  In 
Costa Rica in 1996, the results from an external audit were ignored and over 100 
patients were given an overdose of around 60%.  At least 17 people died in this 
incident due to radiation over exposure [6, 17].  These examples show that it is not 
only very important to regularly perform QA, but it is also essential to cross-check the 
work independently to avoid the same human errors being repeated. 
 
Patient set up 
The position of the patient in the CT scanner must exactly be reproduced under the 
linac.  This is normally done with the aid of any of the following; room lasers, cone 
beam CT scanners, image guided radiotherapy, and portal imaging.  All of these 
systems need to be calibrated, and if this is performed incorrectly errors in the location 
of the delivered dose may occur.  Discrepancies between the linac positioning lasers 
and those of the CT or TPS do occur [18, 19].  For example, if the lasers are 
misaligned the beams can miss significant proportions of a tumour and damage 
enough healthy tissue to adversely affect patient outcome.  The RTs rely on the lasers 
and the tattoos to position the patient.  The lasers are checked as part of the quality 
assurance (QA) process (usually daily), but if they get bumped or moved slightly, the 
positioning of the patient could be out.  The laser position is usually checked daily at 
most centres as part of the QA process. 
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Other potential sources of error 
Other potential sources of error include software and hardware faults.  A software 
error can occur when patient/plan data is transferred from the CT to the TPS or the 
TPS to the linac, the information transferred could potentially be corrupted.  An 
example of a hardware fault is when a ‘sticking’ Multi Leaf Collimator (MLC) changes 
the beam affecting patient treatment. 
 
All the potential sources of error in the various categories mentioned above can cause 
both dosimetric and/or geometric errors which inevitably affect patient outcome. 
 
1.2. Motivation  
Presently in New Zealand there is no external QA process carried out by the NRL 
other than solely checking the machine outputs.  The Trans Tasman Radiation 
Oncology Group (TROG) group has carried out level three audits (see section 1.2.1) 
in New Zealand, though these have not been regular [20]. There is a need for regular 
dose verification in external beam radiation therapy in New Zealand. The ICRU 62 
[21] report details a procedure that addresses this need.  This procedure has been 
implemented in other western countries including Australia [20], the United Kingdom 
[22] and Ireland [23].  The (New Zealand) NRL, as part of its compliance monitoring 
activities, intends to develop such a national dose survey. This procedure, when 
implemented in New Zealand intends to verify the accuracy of the planning and 
delivery of prescribed radiotherapy doses to patients.  This survey is to be developed 
in association with the University of Canterbury and clinical staff in New Zealand’s six 
radiotherapy centres.  The work done in this Masters thesis project provides the basis 
for this audit and is intended to have the capacity to be extended to the auditing of 
more complex techniques, such as Intensity Modulated Radiation Therapy (IMRT) or 
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stereotactic radiotherapy, when these high precision treatment approaches become 
more widely available in New Zealand.   
 
This project creates an approach for an audit that is relevant to radiation therapy in 
this country.  The input of the NRL and the expertise of many clinical staff will be 
taken into account.  The approach is based on an anthropomorphic chest phantom, 
provided by the NRL, to which a prescribed dose is delivered.  Doses received by the 
chest phantom were measured using a Metal Oxide Semiconductor Field Effect 
Transistor (MOSFET) dosimetry system [24] which was provided by the NRL.  This 
project includes the commissioning and calibration of the MOSFET dosimetry system, 
determination of representative tumour volumes, treatment technique and also 
specifies the process which the phantom will go through at each of the centres in 
order to test the full treatment planning and delivery chain. 
 
In order to audit the radiotherapy centres around New Zealand it was decided, in 
conjunction with the NRL, to do an International Commission on Radiation Units 
(ICRU) level three [21] audit with the anthropomorphic chest phantom.  The chest 
phantom for the audit was made by Computerised Imaging Reference Systems 
(CIRS, Norfolk, USA).  The phantom has the proportions based on the chest of a 70 
kg male.  Within the phantom there are three polymers approximating three different 
tissue types.  These polymers types are spatially arranged in the phantom to model a 
person’s spinal cord, lung and soft-tissue.  The densities and electron densities of the 
different polymers are similar to that of a real person so that the behaviour of radiation 
in the phantom will be similar.  Figure 1.2 shows the phantom used and Figure 1.3 
demonstrates the arrangement of the different polymers within the phantom. 
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Figure 1.2 CIRS anthropomorphic chest phantom. 
 
 
 
 
 
Figure 1.3 The arrangement of the different polymers in the phantom. 
 
 
Lung Soft tissue 
Spine 
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1.2.1 The levels of audits 
ICRU 62 [21] defines three levels of auditing the dose at radiotherapy centres.  Level 
3 was decided to be the most relevant for this project.  Details of each level are given 
in Table 1. 
Table 1 The ICRU audit levels 
Level 1: Basic Techniques 
“The minimum requirements for reporting can be followed in all centres including 
those with restricted therapy equipment, dosimetric computer and staff facilities.  This 
level may be sufficient in a centre when only simple treatments are performed, such 
as some palliative treatments.  For this level it is assumed that the dose at the ICRU 
Reference point and an estimation of the maximum and the minimum doses to the 
PTV (Planned Treatment Volume) can be determined.” 
Level 2: Advanced Techniques 
“The standards of Dose planning at this level allow the exchange between different 
centres of more complete and relevant information.  At this level it is assumed that the 
GTV (Gross Treatment Volume), CTV (Clinical Target Volume) and PTV [21] can be 
defined in one or more planes (sections) using reliable patient data acquisition tools, 
and modern imaging techniques under reliable conditions (a series of CT and or MRI 
scans).  It is also assumed that complete dose distributions are computed in the 
central plane and in other planes (sections) using only central axis dose data, and 
with inhomogeneity corrections, when appropriate.” 
Level 3: development of Techniques 
Level 3 includes the development of new techniques for which reporting criteria are 
not yet established (e.g., BNCT2, intensity modulation, etc.). Some procedures, which 
are now at level 3, can become level 2 with the development of techniques, 
equipment and standards. 
 
                                                 
2
 BNCT – Boron Neutron Capture Therapy 
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1.3. The aim and scope of the project 
The aim of this project is to investigate and develop procedures to create an ICRU 
level 3 audit using the CIRS phantom to measure the accuracy of the entire treatment 
chain from imaging to the delivery of the doses with the linac.  This investigation led to 
the creation of the audit protocol, which contains clear instructions of what the 
hospitals are required to do to take part in the audit and also contains the information 
that the NRL needs to collect.  In order to create this level 3 audit we were forced to 
ask the following questions: What exactly do we want to test?  How do we test these 
parameters?  Are our resources and equipment suitable?  Furthermore, the audit 
should also be practical in that it could not be allowed to create a heavy burden on the 
workload of the already busy hospitals, while still getting relevant and meaningful 
dose information.  The protocol also needs to be straightforward in order that it is 
quick and easy for the NRL to adapt.  Part of the project has been the development of 
spreadsheets so that only the raw information has to be entered and the doses along 
with the uncertainties are automatically calculated.  It is hoped that this will ease the 
work of conducting the audit and following the protocol. 
 
The NRL has purchased, along with the CIRS chest phantom, a Thompson and 
Nielsen MOSFET detector system for the purpose of conducting this audit.  It is 
envisaged that in the future this audit could be expanded to encompass more 
complicated radiotherapy treatments, such as IMRT, stereotactic treatment, etc. 
 
1.4. Outline of the thesis 
The commissioning and calibration of the equipment constituted a large part of this 
project.  It was necessary to determine how accurate and reproducible the MOSFETs 
were. Furthermore, the limitations of the phantom had to be determined.  Chapter 2 
deals with the MOSFET detectors, their capabilities and uncertainties, while Chapter 3 
Chapter 1 
 -13-  
details the development of the appropriate treatment plans and procedure for the 
chest phantom that will be carried out for the audit.  Chapter 4 details the 
measurements with the phantom.  In both Chapter 3 and 4 the preliminary phantom 
measurements are the measurements of the phantom with the linac to determine the 
treatments plans and the practice audit runs are the runs of the audit that follow the 
audit protocol in appendix A.  Finally, Chapter 5 discusses and summarises the 
outcomes of this project and discusses future research directions. 
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2. MOSFET detectors 
2.1. Introduction 
MOSFETs are solid state transistors whose technical characteristics are altered by 
exposure to ionising radiation.  This property enables them to be used as radiation 
detectors. There are advantages and disadvantages to using MOSFETs over other 
dosimeter technologies for this purpose.  Some advantages include their small size 
and their ability to be read immediately after irradiation with a push of a button.  They 
are also relatively inexpensive.  They are not more accurate or more reproducible 
than the more commonly used Thermo-Luminescent Dosimeters (TLDs) [25-27], 
however, and are also dependent on energy and angle of the radiation beam relative 
to the MOSFET, which is a disadvantage [28].  
 
This chapter on MOSFET dosimetry includes information on the MOSFET detector 
system that was used for this project, MOSFET theory, and the assessment of 
performance characteristics of the MOSFETs.  This is followed by the uncertainty 
analysis of the MOSFETs.  In the final part of this chapter, all the components of the 
uncertainty from the different parameters are combined to find the overall uncertainty 
in the MOSFETs for the phantom results.   
 
The characteristics and the uncertainty of the MOSFETs had to be assessed to 
determine the suitability of this equipment for the audit.  Uncertainties for the 
confidence level 68% (1σ) of are given for each section of the chapter, with the 
combined uncertainty from all the parameters contributing to the uncertainty of the 
MOSFETs stated for the 95% confidence level (2σ) in the uncertainty analysis section.  
As each parameter is explained and characterised, the contributing uncertainty from 
that parameter in both confidence levels is stated.  The determination of the 
experimental uncertainty of the MOSFETs was a vital part of this project [29].  For the 
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audit to have value, it was necessary to be able to quantitatively state the accuracy of 
the MOSFETs with respect to a given dose [29]. 
 
2.2. MOSFET theory 
MOSFET is an acronym of Metal Oxide Semiconductor Field Effect Transistor.  These 
transistors have three metal contacts (called the source, drain and the gate) attached 
to the layers of semiconductor which have different dopent concentrations.  This 
arrangement is detailed in schematic diagram of a MOSFET in Figure 2.1. 
 
When the voltage of the gate reaches what is called the threshold voltage, current can 
pass through the P type semiconductor from the source to the drain.  Irradiating the 
silicone oxide insulating layer (called gate oxide in Figure 2.1) increases the threshold 
voltage needed for current to pass from the source to the drain.  The threshold voltage 
which is proportional to radiation dose can then be measured by the MOSFET reader. 
 
Figure 2.1  A schematic diagram of a MOSFET.  For the MOSFET to activate, the voltage on the 
gate terminal needs to be sufficient for a channel to form through the N type conductor.  This 
threshold voltage is dependent on the properties of the gate oxide layer. 
 
 
The threshold voltage depends on the properties of the gate oxide layer.  When the 
MOSFET is irradiated holes are trapped in the silicone oxide layer at the edge of the 
N type semiconductor.  In some sense holes are places where electrons would 
otherwise be.  These trapped holes raise the insulating strength of the silicone oxide 
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layer and consequently the threshold voltage is also raised.  During irradiation, a bias 
voltage is applied between the gate and the drain across the MOSFET.  This affects 
the proportion of holes that are trapped in the silicone oxide layer.  For example, a 
MOSFET with a different bias voltage will also have a different threshold voltage than 
a MOSFET irradiated with the same radiation and a different bias. 
 
2.3. The MOSFET dosimetry system 
The MOSFET system that was used in this project was the Thomson & Nielsen 
MOSFET 20 Dosimetry System Model TN-RD-50 (Best Medical, Nepean, Canada).  
This MOSFET 20 system is easily transportable and contains a reader (Figure 2.2), 
four bias supplies (Figure 2.2) and 20 MOSFET dosimeters (Figure 2.3).  
 
The MOSFETs can be read immediately after irradiation.  During the irradiation of the 
MOSFET (which permanently affects their silicone oxide layer), they are plugged into 
the bias supply box.  The bias supply (Figure 2.2) supplies the bias voltage during 
irradiation.  After irradiation the bias supply box is connected to the reader which gives 
a reading of the radiation that the MOSFET was exposed to in mV.  The reader gives 
two readings, the total accumulated voltage and the reading for the last irradiation.  
After each reading the MOSFETs can be zeroed on the reader (though the 
accumulated mV reading cannot be). 
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Figure 2.2 MOSFET 20 reader in the 
background and Bias supply in the foreground. 
 
Figure 2.3 MOSFET dosimeter, the transistor is 
under the black epoxy bubble at the end of the 
dosimeter. 
 
The dosimetry system has two settings, high sensitivity and standard sensitivity.  In 
these different modes the sensitivity of the MOSFETs vary as follows: In standard 
sensitivity an absorbed dose of approximately 1 cGy gives a rise of 1 mV of threshold 
voltage in the MOSFET detector, while in high sensitivity an absorbed dose of 
approximately 1 cGy raises the threshold voltage of the MOSFET by 3 mV.  The 
voltage across the MOSFETs is different for the two settings during irradiation and 
causes the differing responses.  While investigating the capabilities of the MOSFETs 
both standard and high sensitivity were used.  For the part of this project working with 
the phantom, the standard sensitivity mode was used as the MOSFETs are 
disposable and can only be used for a limited life.  The higher sensitivity mode would 
have expended the MOSFETs faster.  The MOSFETs can be used to an accumulated 
voltage of around 20 000 mV [30]. 
 
2.4. MOSFET performance assessment 
In order for the audit to determine the dose at a point in the phantom, the 
characteristics of the MOSFETs had to be assessed and calibration factors 
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determined.  Much of the literature about these detectors details the way the 
MOSFETs capabilities have been assessed previously [26, 28, 31, 32].  The 
characteristics of the MOSFETs that were tested for this project were: reproducibility, 
calibration factors (response per Gy), how and if the calibration factors changed over 
effective dose, energy dependence, fading and, angular dependence.  The dose rate 
with linearity was also considered.  These characteristics were tested prior to using the 
MOSFET system in a clinical environment.  They (and other parameters) were tested 
more thoroughly as more information on specific circumstances of the MOSFET 
behaviour was required as the project progressed.  An example of this increase of 
testing requirements is the angular dependence measurements.  Initially it was 
assumed that the angular dependence would be constant for all energies, however, 
after completing the first test audit run, it was realised that the angular dependence 
must be tested at different energies because the angular dependence is a function of 
the energy of the radiation. 
 
2.4.1 60Co performance assessment 
The MOSFET system’s 60Co performance assessment was performed with the NRL’s 
60Co exposure facility which was a Theratron 80 teletherapy unit which was 
manufactured by the Atomic Energy of Canada Limited (AECL).  It contains a 40 TBq 
60Co source that produces an air kerma rate of approximately 0.16 mGy/min at a 
source distance of 1 m.  To characterise the MOSFETs these detectors were placed 
in a water phantom at a depth of 5cm in a 10cm by 10cm field at a distance of 1 meter 
from the 60Co source at the position of the MOSFET.  The absorbed dose to water 
was determined using the IAEA TRS-398 protocol [33] for 60Co measurements.  The 
set up is shown in Figure 2.4.  A similar set up was used for the higher energy 
measurement with the linac.  The beam was first measured by using an ionisation 
chamber with an absorbed dose to water calibration traceable back to a primary 
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standards laboratory.  This gave accurate beam output data of the 60Co source, which 
enabled the determination of the calibration factors of the individual MOSFETs.  The 
MOSFETs were put into the same cavity as the ionisation chamber in a purpose built 
perspex sleeve (Figure 2.5).  The sleeve was made so the MOSFET would fit snugly 
in the cavity for the ionisation chamber, as the Ionisation chamber is significantly 
larger than the MOSFET. 
 
 
Figure 2.4 The water phantom in which the MOSFETs were calibrated according to TRS-398 
protocol.   
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Figure 2.5  Perspex sleeve for MOSFETs which was used in all water phantom measurements with 
the MOSFETs. 
 
2.4.2 Reproducibility 
For a repeated dose given to a MOSFET, the reading obtained for each can vary by 
several percent.  This variation in the reading, or the reproducibility, was investigated.  
This was an important part of the assessment of the MOSFET detectors as this 
parameter was likely to be a large component of the combined uncertainty as reported 
by other researchers [34].  The manufacturer states [30] that these MOSFETs have 
reproducibility that is shown in Table 2. 
Table 2 Reproduction of manufacturers’ information [30] on the reproducibility of the MOSFETs.  
These are to a confidence level of 68% using 60Co. 
 
Dose Bias supply sensitivity 
 High Standard 
200 cGy <0.8% <2% 
100 cGy <1.2% <3% 
20  cGy <3 % <8% 
 
To find the reproducibility of the MOSFET, individual MOSFETS were irradiated 10 
times with the following doses: 0.5 Gy on high sensitivity and 1.0 Gy on standard 
sensitivity.  These doses were chosen for economic reasons as well as equipment time 
Perspex sleeve 
MOSFET cable 
Sensitive element of 
MOSFET 
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restraints.  The results for standard and high sensitivity are shown in Table 3 and Table 
4 respectively.  Note that an individual MOSFET was tested either on high or standard 
sensitivity, not both.  These tables show that some of the MOSFETs were more 
reproducible than others.  The MOSFETs that were determined to be noisy (MOSFETs 
with a high relative standard deviation) were not used for the practice audit runs.  
Whether or not a particular MOSFET was too noisy was decided on an individual 
basis. 
 
Standard sensitivity 
Table 3 The reproducibility of the MOSFETs on standard sensitivity irradiated ten times with 1 Gy in 
60Co 
MOSFET No Average (mV) Standard deviation (mV) Relative std Deviation (%) 
2930 115.0 2.1 1.8 
2927 115.3 2.9 2.5 
2949 113.7 1.4 1.2 
2861 113.6 2.5 2.2 
2919 116.1 2.3 2.0 
 
The reproducibility in standard sensitivity was found to be similar to the 
manufacturers’ claims [30], with the reproducibility being <3% for a confidence level of 
68% on standard sensitivity. To improve the accuracy of the measurements of the 
doses to the phantom, it was decided that each treatment plan would be repeated 3 
times.  The contributing uncertainty from the reproducibility was then taken to be the 
largest standard error3 from Table 3 the reproducibility measurements on standard 
sensitivity.  The contributing uncertainty that was considered most representative of 
the MOSFETs that were tested was taken to be MOSFET 2919 with a standard 
deviation of 2.0%.  The standard error of this is 1.15% assuming that three 
                                                 
3
  Please note that the standard error is not the same as the standard deviation, the standard 
error is the standard deviation divided by square root of the number of measurements. 
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measurements will be taken in the audit.  This is the value that will contribute to the 
combined uncertainty of the MOSFETs. 
 
High sensitivity 
Table 4  The reproducibility of the MOSFETs on standard sensitivity irradiated ten times with 0.5 Gy 
in 60Co 
MOSFET No Average (mV) Standard deviation (mV) Relative std deviation (%) 
2933 158.4 2.9 1.8 
2932 158.1 1.9 1.2 
2931 156.9 2.0 1.3 
2912 160.6 1.3 0.8 
2935 157.0 1.9 1.2 
 
The MOSFETs on high sensitivity also showed similar results to the manufacturer’s 
claims (Table 2) [30].  The 68% confidence level for the standard error of the 
MOSFETs on this sensitivity was found to be <0.6%.  This value was obtained using 
the largest relative standard error in the high sensitivity reproducibility measurements.  
 
Measurements in this project on high sensitivity were done for completeness.  Since in 
the audit, or the preliminary phantom measurements, no MOSFETs were used on high 
sensitivity.  Uncertainties from this source (MOSFETs irradiated in the high sensitivity 
mode), do not contribute to the overall uncertainty of the MOSFETs used in the 
phantom in this project.  
 
2.4.3 Calibration Factor 
Calibration factors were obtained for a total of thirteen MOSFETs.  The calibration 
factor was the dose given divided by the response of the MOSFET.  As the calibration 
factors varied significantly between the MOSFETs it was necessary to obtain a 
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separate calibration factor for each MOSFET.  To obtain these calibration factors, the 
MOSFETs were irradiated with 1.5 Gy in 60Co three times each.  This dose was 
decided to be a good compromise between expending the MOSFETs too quickly and 
obtaining accurate calibration factors.  Each MOSFET was irradiated three times to 
obtain the calibration factor, with the calibration factor calculated using the average of 
the three measurements. 
Table 5 Each MOSFET with their own specific calibration factor along with the standard error 
 
MOSFET No Calibration Factor (cGy/mV) Relative standard error (%) 
2930 0.891 0.8 
2861 0.878 0.9 
2949 0.896 0.6 
2912 0.932 0.9 
2935 0.942 0.4 
2929 0.882 0.9 
2915 0.892 1.1 
2032 0.928 0.8 
2931 0.945 0.4 
2933 0.929 0.8 
2947 0.887 1.1 
2950 0.907 0.9 
2919 0.874 1.6 
 
MOSFET number 2919 was identified as being particularly noisy and so was not used 
in any of the testing or audits in the phantom.  The large standard error of this 
particular MOSFET was also not considered for the overall uncertainty analysis that is 
presented at the end of this chapter. 
 
The contributing uncertainty from the MOSFET calibration was taken from the greatest 
value of the standard errors in Table 5 (except from MOSFET 2914).  This makes the 
contributing uncertainty from the calibration factor to be 1.1% with a confidence level of 
68% and 2.2% with a 95% confidence level. 
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Accumulated dose dependence of the calibration factors 
It was necessary to determine whether the calibration factors remained constant as the 
voltage across a MOSFET increased. To test this MOSFETs that had already been 
calibrated and in some cases had already had significant dose on them, were re-
calibrated after they had acquired more voltage across them.  The stability of the 
MOSFETs’ calibration factors’ were examined.  The uncertainties from both the first 
and second calibration factors were combined to give the combined uncertainty column 
in Table 5. The MOSFETs are listed in descending order of accumulated effective dose 
between the two calibrations.  Not all the MOSFETs were recalibrated as it was 
undesirable to expend too much of their effective dose capacity. 
 
As can be seen from, Table 6 the calibration factor changed, sometimes this change 
was greater than the combined uncertainty of the calibration factors.  To determine if 
there was any pattern to the change in calibration factors with dose (as there did not 
seem to be), more measurements of the calibration factor were taken. 
 
Table 6 The change in calibration factor as the MOSFETs acquired more voltage across them. 
 
MOSFET # 
1st calibration 
factor 
(cGy/mV) 
Accumulated 
voltage (∆ mV) 
2nd calibration 
factor (cGy/mV) 
Combined 
uncertainty 
(%) 
Relative change in 
calibration factor 
(%) 
2930 0.891 4116 0.926 1.4 3.9 
2861 0.878 4900 0.885 1.0 0.8 
2912 0.932 3849 0.892 1.1 -4.3 
2929 0.882 2461 0.911 1.2 3.2 
2914 0.874 1326 0.884 1.9 1.1 
2931 0.945 1282 0.923 1.0 -2.3 
2933 0.929 814 0.917 1.1 -1.3 
 
 
Chapter 2 
 -25-  
Reproducibility over a large dose 
To determine if the calibration factor changed as a function of the total voltage across 
the MOSFET, or the calibration factor changes were solely a function of reproducibility, 
a MOSFET was irradiated with 1.5 Gy thirty six times with the total dose over 120 Gy.  
This gave information on the change in response over a large range of accumulated 
voltage.  The MOSFETs’ accumulated voltage was equivalent to 60 Gy of dose on 
standard sensitivity. 
Relationship of MOSFET response with rising accumulated voltage
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Figure 2.6 This graph suggests that there is an upwards trend in response as the voltage across 
the MOSFET increases. 
 
 
There is a slight upwards trend shown in Figure 2.6.  The graph shown in Figure 2.7 is 
perhaps more relevant since it shows the running average of three measurements, 
which is the number of measurements which will be taken at the audits. It shows that 
there is a trend upwards that is significant.  Consequently it was decided that a 
MOSFET must be re-calibrated after around 3000 mV of accumulated voltage, which 
corresponds to an irradiated (effective) dose.  The interval of 3000 mV of accumulated 
voltage was selected the change in response was approximately 2%. 
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Running average of 3 measurements with rising voltage
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Figure 2.7 This graph shows that the average of three sequential measurements of a MOSFET 
 
 
To obtain as accurate as possible results for the audit, it was decided that henceforth 
the MOSFETs should be recalibrated immediately before an audit. 
 
 
2.4.4 Angular Dependence 
MOSFETs are known to have angular dependence, with different researchers having 
reported a wide range of variations in response to angle [28, 35].  Therefore, it was 
very important to determine the angular dependence of the MOSFETs that were used 
for the audit.  To perform this, four MOSFETs were irradiated with the 60Co source, in 
the water phantom set up in section 2.4.1, at angles ranging between 0 and 180 
degrees in 45 degree increments.  The MOSFETs were rotated counter clockwise 
(facing the plug end of the MOSFET) around the axis running length wise as shown in 
Figure 2.8.   
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Figure 2.8 Diagram clarifying the angular dependence measurements.  The MOSFET was rotated 
in the direction of the blue arrow and readings of response were taken at various angles. 
 
All irradiations were performed with the bias supply on standard sensitivity.  Each 
MOSFET was irradiated three times with 1.5 Gy at each angle to obtain more accurate 
results. Figure 2.9 shows the change in response with angle for these trials.  The 
MOSFET response was the least when the MOSFETs epoxy bubble was 90 degrees 
to the incident radiation beam.  
 
The angular dependence, shown in Figure 2.9, demonstrates that there is a significant 
contribution to the combined uncertainty from angular dependence of the MOSFETs 
with the 60Co.  The MOSFET manual [30] states that the angular dependence values 
for irradiations 1-20 MeV is 2% for 360 degrees of rotation.  Figure 2.9 shows that the 
angular dependence for 60Co (with gamma emissions at 1.33 and 1.17 MeV [36]) is 
more than this.  However, after conducting angular dependence measurements with 6 
and 18 MV photons (Figure 2.10 and Figure 2.11 respectively), it was found that the 
results were closer to that of the manufacturers’ claims [30] than the 60Co, though the 
angular dependence remained larger than the manufacturer’s claims.   
Direction of 
incident 
radiation 
MOSFET 
irradiated at 
varying angles 
to incident beam 
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Figure 2.9 This graph shows that the angular dependence of the MOSFETs in 60Co is 
approximately sinusoidal.  There was a variation of the amplitude from 6 to 10 percent for the 
different MOSFETs 
 
To obtain information on the angular dependence of the MOSFETs that were to be 
used in the practice audit runs, the MOSFETs used were, for economical reasons only 
irradiated at 0 and 90 degrees  (at both 18 and 6 MV for completeness). This was 
because it was undesirable to expend the capacity of the MOSFETs more than was 
necessary.  
 
Figure 2.10 shows the percentage drop in response at 90 degrees with 6 MV photons. 
It was determined that the drop in response at 90 degrees to the beam for the 
MOSFETs used in the final stages of the practice audit run ranged from 2.3% to 3.9% 
with an average of 3.3%.  Currently, the treatment plans for the audit solely use 6 MV 
photons so the correction factor for the angular dependence was determined from 
these measurements. 
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Angular dependence at 6 MV
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Figure 2.10 Angular dependence of the four MOSFETs at 6 MV.  The angular response was tested 
only at angles of 0 and 90 degrees.  The error bars represent one standard deviation 
 
As in the audit the MOSFETs will be used to measure 6 MV, the uncertainty in the 
angular dependence with this energy counts towards the combined uncertainty in the 
MOSFETs used in the audit.  The contributing uncertainty of the MOSFETs from the 
angular dependence is 0.33% with a confidence level of 68%  
 
The percentage drop for 18 MV (Figure 2.11) showed similar results with an average 
drop of 2.8%.  This is close to the manufacturers’ claims of 2%, but if in the future the 
audit uses 18 MV in the treatment plans, correction for the angular dependence would 
be necessary. 
 
Chapter 2 
 -30-  
Angular dependence at 18 MV
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Figure 2.11  Angular dependence of the four MOSFETs tested at 18 MV.  These MOSFETs used 
for the final stages of the preliminary audit run.  The angular response was tested only at 0 and 90 
degrees.  The error bars represent one standard deviation. 
 
The angular dependence was significantly different between 60Co and 6 MV and 18 MV 
suggesting that the angular dependence varies with energy.  This has been reported 
by other researchers [37], who noted that the angular dependence dropped up to 28% 
for photons in the keV range.  The magnitude of the differences in response indicates 
that the angular dependence should always be corrected for.  That is, at all angles 
except zero, a factor correcting for angular dependence is required.   
 
 
Deriving the relationship of the angular dependence 
To derive the angular relationship of the angular dependence, it was initially assumed 
that the angular dependence would be symmetrical around 180 degrees.  It was later 
realised that this symmetry could be further investigated, this was not done in this 
project due to both time constraints (each measurement took ten minutes with the 60Co 
source) and also to avoid expending the MOSFETs effective dose capacity.  As can be 
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seen from Figure 2.12, the curve of best fit approximates a sine curve (the curve below 
is in reality a polynomial).  
  
The stretched out sine curve derived was; )180/1.39.0sin(06.01 ×+ .  It was 
assumed that the shape of the curve for the angular dependence for 60Co and the 6 
MV photons would be the same with the exception of different amplitude. 
 
 
Figure 2.12 The curve above approximates a sine curve, a relationship of the drop on response 
with angle was derived. 
 
 
2.4.5 Linearity 
Linearity is the response of the MOSFET as a function of the dose irradiated.  This was 
an important characteristic to test as if this function was not linear, the curve would 
have to be calculated and corrections for this curve applied so accurate doses 
measured with the MOSFETs could be obtained.  The linearity was measured on both 
high and standard sensitivity. 
 
 
Standard sensitivity 
The linearity of the MOSFET on standard sensitivity was tested in a similar way.  Five 
measurements were taken at five varying doses to obtain the linearity as shown in 
Figure 2.13.  Each error bar in this figure represents one standard error. 
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Linearity of MOSFET on standard sensitivity
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Figure 2.13 Linear relationship of MOSFET on standard sensitivity 
 
It was found on standard sensitivity that there was a strong linear relationship with 
dose.  As with the high sensitivity measurements, the line of best fit passes well within 
all the error bars for the standard sensitivity measurements.  The strong linearity 
shown by the MOSFETs at both sensitivities shows that, for the doses investigated, the 
MOSFET radiation detectors will be suitable for the audit without any corrections 
factors for linearity needed. 
 
The linearity with dose rate was also considered.  This was assumed to be taken into 
account with the comparison (and the consequent correction factor applied) between 
the 60Co source (low dose rate) and the linac (high dose rate) measurements in section 
2.4.7. 
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High sensitivity 
To find the linearity of the MOSFETs on high sensitivity, five measurements were taken 
at six varying doses using the 60Co source to accurately determine the linearity.  
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Figure 2.14 The linearity of the MOSFET on high sensitivity 
 
 
These tests showed that the MOSFET had excellent linearity of response at high 
sensitivity.  Figure 2.14 shows this linear relationship, with the line of best fit passing 
well within all the error bars, where each error bar represents one standard error.  
 
 
2.4.6 Fading 
MOSFETs can fade if they are not read immediately after irradiation.  This means that 
the response in mV is lower if MOSFETs were read some time after irradiation instead 
of immediately.   According to the MOSFET manual [30] this is less than 3% of 2 Gy 
when read within 15 minutes of exposure.  This was measured with the MOSFETs that 
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were used for this project.  The MOSFETs were irradiated with 1.5 Gy with the 60Co 
source and then read after five, ten, and fifteen minutes; this was repeated three times.  
No fading was observed in these measurements. 
 
 
2.4.7 Energy Dependence 
To assess the energy dependence in the response of the MOSFETs, three MOSFETs 
were irradiated with 1.5 Gy with the 60Co source and also 18 MV and 6 MV photons 
from the linac which was a Varian 21iX S/N 1009 model.  Figure 2.15 shows the 
relative response of the MOSFETs which demonstrates that 18 MV gave the lowest 
response and Co 60 the highest. 
 
The contributing standard error to the combined uncertainty of the MOSFETs from the 
energy dependence is 1.1% with a confidence level of 68%.  This is from the standard 
error of the distribution of the energy dependences from the individual MOSFETs 
tested. This uncertainty is only relevant to the preliminary phantom measurements, not 
the practice audit runs as the MOSFETs used in the practice audit runs all had 
calibrations factors obtained for them in 6 MV photons.  This was found to be 
consistent with other research [38]. 
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Energy dependence of MOSFETs
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Figure 2.15  Graph showing the relationship between the MOSFET calibration factor with changing 
energy and TPR4 [39] value. 
 
2.5. The worksheet 
An excel worksheet was created to apply all the corrections from the parameters 
characterised in this chapter, which calculates the dose to the MOSFET.  Only the 
beam angles, the MOSFET locations in the phantom, the MOSFET number and 
response, are required to be entered into the worksheet.  The worksheets can be 
found in Appendix B.  The worksheet was created for ease of analysis, and also so the 
results could be entered into the worksheet during irradiations of the phantom with the 
doses given immediately.  It will also lighten the burden for the NRL to analyse the 
results in future audits. 
 
                                                 
4
 TPR stands for Tissue Phantom Ratio and is defied as the ratio of the dose at a given point in 
phantom to the dose at the same point at a fixed reference depth usually 5 cm.  
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2.6. Uncertainty analysis 
The uncertainly analysis was a vital part of this project.  In the audit, it needs to be 
stated within what accuracy the MOSFETs can give information on the dose.  To find 
the total uncertainty of the MOSFETs all the correction factors and their associated 
uncertainties needed to be taken into account.  The uncertainty in the dose 
determination when using the MOSFETs was found using the principles according to 
the guidance in International Organisation for Standardisation’s ‘Guide to the 
Expression of Uncertainty in Measurement’ (ISO guide)  [29]. 
 
Not all the MOSFETs were calibrated in the same manner for all the runs in the 
phantom.  For example, the MOSFETS used in the first trials with the phantom under 
the linac, and the MOSFETs used in the practice audit runs were calibrated slightly 
differently, thus the uncertainty analysis is not the same for the two sets as one of 
these sets does not include the uncertainty in the energy dependence.   
 
For the first runs with the phantom under the beam, the MOSFETs were calibrated 
using the 60Co source and a correction factor for the energy was applied.  For the 
practice audit runs, information was obtained about the characteristics of those 
particular MOSFETs for the photon energies used in the audit.   
 
2.6.1 General uncertainties 
According to the ISO guide [29] there are two types of uncertainties, they are: 
 
A Type A method of evaluation of uncertainty is by the statistical analysis of a 
series of observations. 
B Type B method of uncertainty is by means other than the statistical analysis of 
a series of observations 
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With one exception, all the uncertainties of the MOSFETs were type A uncertainties as 
they were determined by statistical analysis.  The exception to this is the uncertainty in 
the angles that were not in 45 degree increments between 0 and 180 degrees, as the 
angular dependence between these increments were interpolated between the data 
points.  Since that in both the preliminary phantom measurements and the practice 
audit runs the MOSFETs were at angles to the beam that were not in 45 degree 
increments from zero, there is an uncertainty associated with these angles that are not 
from statistical analysis.  Thus an estimated uncertainty of 0.5% was added to cover 
this type B uncertainty. 
 
In this section all the factors of the uncertainty that were taken into account will be 
indentified. The errors and where they come from are outlined below. 
 
Table 7 The contributing uncertainties to the combined uncertainty of the MOSFETs 
Type A 
uncertainties 
Contributing 
uncertainty Type B uncertainties 
Contributing 
uncertainty  
Reproducibility 0.8% Interpolation of angles 0.5% 
Calibration factor 1.1%  
Angular 
Dependence 6 MV 0.3% 
 
 
 
 
 
Energy Dependence 1.1%  
 
 
 
 
All the type A uncertainties were found by finding the standard error of the group of 
measurements that tested those particular characteristics.  The equation to find the 
delivered dose from the MOSFET response using TRS-398 [33] is: 
 
Equation 1  
iareaQWDQQw kkkkNMD o ×××××= ....  
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Where: 
Symbol Definition 
Dw.Q the absorbed dose to water in a water phantom at 
reference depth with a beam quality Q 
MQ The MOSFET reading 
ND.W.Q The calibration factor of the MOSFET 
ka correction factor of the angular dependence of the  
MOSFET 
ke energy correction factor 
kr Correction factor for the reproducibility, equal to one, but 
does have a contributing uncertainty 
kia Correction factor for the interpolations between the data 
points in the angular dependence, equal to one, but does 
have a contributing uncertainty 
 
 
Since all the correction factors are multiplicative, the combined uncertainty, according 
the Guide to the Expression of Uncertainty in Measurement  [29],  is the positive 
square root of the combined uncertainties squared.  The coverage factor used was 
two; this was chosen to give a confidence level of approximately 95% in the MOSFET 
results, though the sample size in the audit may be sufficiently small to warrant a 
coverage factor in excess of 2.  
 
2.6.2 Combined uncertainty in preliminary phantom measurements 
For the uncertainty of the doses given by the MOSFETs used in the first trial runs with 
the phantom, the energy dependence, angular dependence, reproducibility, and 
uncertainty in the calibration factor were taken into account: 
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Table 8 The combined uncertainty for the MOSFETs in the preliminary phantom measurements. 
Type A 
uncertainties 
Contributing 
uncertainty Type B uncertainties 
Contributing 
uncertainty  
Reproducibility 1.15% Interpolation of angles 0.5% 
Calibration factor 1.1%  
Angular 
Dependence 6 MV 0.33% 
 
 
 
 
 
Energy Dependence 1.1% 
 
 
Combined 
uncertainty 2.0% 
 
Expanded 
uncertainty 4.0%  
 
 
2.6.3 Combined uncertainty in the audit practice run 
The MOSFETs used the audit run all had calibration factors obtained with 6 MV 
photons, hence the energy dependence uncertainty is not factored in. Consequently in 
this case, the contributing uncertainties are the uncertainties from the angular 
dependence, reproducibility, and the calibration factor. 
 
Table 9 The combined uncertainty for the MOSFETs in the practice audit run. 
Type A 
uncertainties 
Contributing 
uncertainty Type B uncertainties 
Contributing 
uncertainty  
Reproducibility 1.15% Interpolation of angles 0.5% 
Calibration factor 1.1%  
Angular 
Dependence 6 MV 0.33% 
Combined 
uncertainty 1.7% 
 
 
 
 
 
 
 
Expanded 
uncertainty 3.4%  
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These uncertainties are within the target of ± 5% that the ICRU Report 62 [21] 
recommends for the reporting of doses in radiotherapy audits. This means that the 
MOSFET dosimetry system can be employed for the audit, and any doses outside this 
recommended range will be detected.   
 
Including both the reproducibility uncertainty and the calibration uncertainty could be 
considered to be taking the same uncertainty into account twice because both are 
direct functions of the standard deviation in the MOSFETs measuring a dose under the 
same conditions.  Both of these uncertainties were included to eliminate the possibility 
of underestimating the combined uncertainty of the MOSFETs. 
 
2.7. Summary and discussion 
 
The MOSFETs were characterised with both 60Co source and 6 MV and 18 MV 
photons with the linac.  To do this the MOSFETs were placed in a water phantom in a 
depth of 5 cm with the 60Co source, and a depth of 10 cm for the measurements with 
the linac.  The machine and beam outputs were first measured with the NRL’s 
ionisation chamber whose calibration factor can be traced back to a primary standards 
laboratory. 
 
The MOSFET characteristics that were tested were the reproducibility of response, 
stability of calibration factors, angular dependence, linearity, and energy dependence.  
Most of these parameters were tested with the 60Co source, and some parameters 
should be tested more thoroughly in future work.  For example, the linearity at low 
doses of the MOSFETs should be further characterised and more information about 
how the angular dependence varies with dose rate and photon energy is also needed. 
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It was found that the reproducibility of the MOSFETs was within about 2% on standard 
sensitivity, and it was decided that any phantom measurements should be performed 
at least three times to obtain accurate results.   
 
The calibration of the factors did not stay stable with large increases of effective dose 
on the MOSFETs.  It is recommended that new calibration factors should be obtained 
after 3000 mV of effective dose.  This is because after this effective dose, the change 
in response was approximately 2%. 
 
The angular dependence was found to be significant, the drop in response with the 
MOSFETs at 90 degrees to the beam was found to be approximately 6% with the 60Co 
source and 3.3% and 2.8% with 6 MV and 18 MV photons respectively.  
 
The linearity of MOSFET detectors was found to be highly linear with dose for both 
high sensitivity and standard sensitivity measurements.  The energy dependence was 
also characterised.  It is recommended that the MOSFETs used for future audit runs 
should be first calibrated with 6 MV photons and the drop in response with the 
MOSFET at 90 degrees for each individual MOSFETs should also be determined so 
more accurate results can be obtained for the future audit runs.  No fading was 
observed in the MOSFETs. 
 
The uncertainty of the MOSFETs was calculated according to the ISO guide, and 
included a coverage factor of 2 to give a confidence level of approximately 95%.  Each 
MOSFET could potentially have its own uncertainty calculated individually, but in the 
uncertainty section of this chapter, general uncertainties demonstrative of all the 
MOSFETs‘ uncertainties were calculated.  The main sources of uncertainties were the 
contributing uncertainties from the reproducibility and the calibration factor.  The 
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calculated combined uncertainty with a coverage factor of two was calculated to be 
4.0% and 3.4% for the preliminary phantom measurements and the practice audit runs 
respectively. 
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3. Treatment planning and audit protocol 
3.1. Rationale 
This chapter details the process of determining the treatment plan(s) to be used for the 
audit.  The processes that the phantom will go through for collecting pertinent 
information at each centre are also addressed.  As well as the planning, this chapter 
also discusses the formation of the audit process, and the creation of the audit protocol 
(Appendix A).  The protocol contains detailed information and instructions to inform the 
centres of the individual steps of the audit process.  The protocol also informs the 
centres of what they are required to do to participate in the audit.  A number of 
diagrams have been repeated in this chapter and the subsequent one for ease of 
reference. 
 
Determining a suitable procedure for the audit was the most crucial aspect of this 
project.  Consequently a considerable proportion of the work for this project was spent 
on this task.  The following variables had to be decided upon; the kind of audit 
employed (see section 1.2.1), the parameters to be measured, the doses (magnitudes 
and modalities etc) to be delivered, and the manner in which data was to be collected 
and analysed.  The audit had to be practical and an acceptable burden on the busy 
centres, but it also had to collect enough information to be useful.  It was decided that it 
would be best to keep the audit simple, at least for the first run since it could always be 
expanded to encompass more complicated parameters in the future. 
 
Developing the procedure for the audit was not a trivial task.  It was decided relatively 
early in the project that the centres would carry out specified treatment plans, since this 
allows a dose intercomparison between the centres.  The alternative was that the 
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centres created their own plan(s), given a specified diagnosis and dose to a volume to 
the ‘patient’. 
 
Whether the CT data of the phantom would be given to the centres or the centres 
would collect it themselves required much thought.  This is because the possible 
discrepancies in the CT to density conversion tables in the respective TPSs between 
the centres could introduce more errors in the final dose.  Advantages and 
disadvantages of including this possible source of error were considered.  The 
advantage was that if the CT data was supplied, it could have been easier on the 
centres as a CT appointment would not have needed to be made. One disadvantage 
was that if this contributed an error which affected patient doses, then it would not be 
found by the audit.  Another disadvantage was possible import problems of the CT 
data into the various TPSs. 
 
Plans also had to be designed to establish under which conditions doses could be 
measured with the MOSFETs.  For example, could doses be measured accurately in 
the lung in a lung insert, with a different density to that of tissue [40]?  A treatment plan 
had to be designed and executed in order to determine this.  This is detailed in section 
3.2.1 with the results shown in section 4.1.2. 
 
3.2. Determining the treatment plan 
There were two options for the method considered for the audit. One option was to 
provide the treatment plan and the dose, while the other was to provide the dose only 
and leave the specific treatment plan parameters up to the centres.  It was decided 
relatively early on that the treatment plans that the centres would use to treat the 
phantom would be specified.  This decision was made so a direct comparison of the 
doses could be made between the centres, whereas if the plans were designed by 
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each centre, they would all be different, consequently making a direct intercomparison 
impossible.  While deciding on plans various ideas were discussed, all of which had 
some advantages and disadvantages. Some involved the inclusion of more 
complicated beam parameters. Using more complex beam parameters would have 
tested the capabilities of the TPSs to a greater extent, but would have significantly 
increased the work load of the centres, as well as introducing more sources of possible 
errors in the overall doses administered to the phantom. 
 
The first step was to determine a representative tumour volume in the CIRS phantom.  
The size and location of the tumour volume was restricted by the inserts of the 
phantom.  The treatment volumes had to be the last three centimetres of the cylindrical 
insert since this is where the MOSFET detectors could be placed within the phantom 
(see Figures 1.2 and 1.3).  Since the tumour volume was specified to be the last three 
centimetres of the insert, the treatment volume extended to 1.5 cm either side of where 
the MOSFETs could be placed (Figure 3.1).  
 
Before any on the treatment plans could be finalised, it was necessary to determine 
whether the dose to the lung could be measured accurately given that the density of 
the lung material, both in real people and the phantom, is much smaller (0.25 to 0.37 
g/cm-3 [41]) than that of water.  This is because the charged particle equilibrium 
conditions also differ in this lower density material.  This is further outlined in section 
3.2.1.  The treatment plans were all created using the treatment planning system at 
Christchurch hospital, which is the CMS XIO Treatment planning system (CMS, St 
Louis, USA).   
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Figure 3.1 The end 3 cm of the insert as shown was chosen to be the tumour volume.  Note that 
only half of the chest phantom is shown here. 
 
 
3.2.1 Preliminary lung plan 
For standard dosimetry measurements in radiotherapy, a certain set-up with defined 
conditions is used. It was not known how the differing charged particle equilibrium 
conditions would differ in the lung tissue since the charged particle equilibrium could 
occur at different depths due to the different density of the lung tissue.  Thus, a plan 
was designed to treat a volume in the lung.  Since the preliminary lung treatment plan 
was only intended to determine whether the MOSFETs could accurately measure 
doses in this lower density medium, the plan was straightforward.  It consisted of two 
parallel opposed beams using 6 MV photons without wedges or collimators with field 
sizes of 4cm by 4cm, giving a total dose of 2 Gy to the lower insert in the lung (see 
3 cm 
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Figure 3.2).  Two plans were investigated, one with the lung insert and one with the 
tissue insert as the tumour volume. 
 
Figure 3.2 The preliminary lung plan.  The blue crosses mark the interest points where the doses 
were measured and compared with the TPS values. 
 
Since there was no cavity in the centre of the lung insert for the MOSFETs to be 
placed, the dose had to be measured at the interest points at the edge of the tumour 
volume (see Figure 3.2).  The plan was designed such that a uniform dose could be 
delivered to the tumour volume. 
 
Measurements with the lung insert in place showed that the MOSFETs measured the 
dose accurately. The measured doses obtained in the treatment volumes were within 
2% of the Christchurch’s XIO TPS, with the TPS giving 1.96 Gy and 2.07 Gy to near 
the top and bottom of the tumour volume respectively.  Since the results were within 
2%, they were well within the uncertainty of the MOSFETs, which is 3%.  This plan was 
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carried out three times to acquire accurate dose information from the MOSFETs.  
Based on these results, it was decided that a lung plan could be considered for the 
audit. 
 
TPSs can often have difficulty calculating dose where there are sharp density changes 
[42]. It was unknown whether charged particle equilibrium existed, consequently a very 
similar plan to that of the preliminary lung plan was carried out with the only alteration 
being the use of the tissue insert in the lung instead of the lung insert as the treatment 
volume (see Figure 3.3).  With the use of the tissue insert instead of the lung insert, the 
doses were 2% and 4% higher for the interest point doses at the top and bottom of the 
tumour volume respectively. 
 
 
Figure 3.3 The Tissue insert was placed in the lung to compare the values with the lung insert 
 
 
The use of the tissue insert in the lung could potentially mimic more accurately a 
typical tumour in the lung than the lung insert would, as tumours quite often have a 
Tissue insert 
in lung 
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density close to that of tissue [43].  Though sometimes the tumours can be strewn out 
(disseminated) with no significantly sizable mass with a density close to that of tissue 
[44].   
 
Both of these preliminary lung plans gave excellent results (the results from the parallel 
opposed lung plan are detailed in section 4.1.2.), demonstrating that the MOSFET 
detectors can be used in the lung with both the lung and the tissue insert, which means 
that the use of a lung plan for the audit using the MOSFET detectors was a possible 
option.  
 
3.2.2  The mediastinum plan 
The mediastinum plan was originally part of the preliminary phantom measurements 
to help decide what treatment plan(s) would be used for the audit.  It was named the 
mediastinum plan as it delivered a dose to the centre of the chest phantom, which in a 
real person would be called the mediastinum.  It was decided after the preliminary 
phantom measurements that this plan would be included in the audit.  It was also 
elected that one of the plans should be kept relatively simple, with no wedges or 
complicated beam parameters, and also avoiding any sharp density changes around 
the treatment volume.  The mediastinum plan had all these desired qualities.   
 
The mediastinum plan was designed to deliver a dose of 2 Gy to the centre of the 
central insert in the phantom using parallel opposed beams going posteriorly and 
anteriorly with a 5cm by 5cm field with 6 MV photons (Figure 3.4).  The beam at 
gantry angle of 0 degrees (going anteriorly to posteriorly) had a dose weighting of 
0.45, whilst the beam at 180 degrees (posteriorly to anteriorly) had a dose weighting 
of 0.55 relative to the dose prescription point.  The mediastinum plan with the isodose 
lines is shown in Figure 3.5. 
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Figure 3.4 The mediastinum plan, using 6 MV photons and a 5 cm by 5 cm to the central phantom 
insert delivering a dose of 2 Gy. 
 
As mentioned previously, a simple treatment plan has advantages. This is because if 
there are any discrepancies between the TPS dose and the measured dose, then 
there would be fewer possible sources of error from which such discrepancies might 
occur.  Consequently, any potential sources of error would be easier to isolate. 
 
The main complicating factor in this plan was the different density of the spinal cord 
through which one of the two beams had to pass.  The results from these plans and 
the practice audit runs are in Chapter 4.  Note that the mediastinum plan was 
originally performed at the same time as the preliminary lung plan, and the 
mediastinum plan was not altered for the audit.  However, the MOSFET detector 
positions, and thus the acquired interest point doses, were different in the first run of 
this plan than they were in the final audit protocol.  This is because in the preliminary 
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phantom measurements the purpose was to ensure that the equipment was capable 
of performing in these conditions, and the point doses were not chosen for the 
maximum efficacy of gathering information for the audit, but rather to ensure that the 
equipment was working as it should.  
 
Figure 3.5  Mediastinum plan with isodose lines 
 
For this initial run of the mediastinum plan all the measured doses were in agreement 
with the TPSs calculated doses of which all were within the uncertainty of the 
MOSFETs (this is detailed in section 4.1.1).  The Dose Volume Histogram (DVH) of 
the mediastinum plan is included for with the results in Chapter 4.   
 
The DVHs of the various treatment plans are included as they enable the comparison 
of different treatment plans’ dose distributions.  The dose distribution is important for 
patient outcomes as the percentage of a tumour to receive a particular dose impacts 
tumour control.  It is also important to calculate the percentage of a particular organ 
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receiving a certain dose, as this is a factor in organ toxicity.  The dose grid size for all 
the presented DVHs is 0.3 cm in three dimensions. 
 
3.3. Clinical lung plan 
The drawback of having a simple plan was that it did not test any of the more complex 
dose calculations of the TPSs, for example, dealing with the lung to tissue density 
changes, or the use of wedges.  Thus it was decided that a more complex plan, closer 
to a real clinical plan, would also be included in the audit. 
 
To construct a good lung plan there are many factors to consider, because although it 
is important to get the full prescribed dose to the tumour, it is also important to do as 
little damage as possible to the surrounding tissue.  In this case the organs at risk 
include the lung where the treatment volume lies, the contra-lateral lung, and the spinal 
cord.  Increased dose to the surrounding lung can have adverse side effects such as 
scarring.  While, an increased dose to the spinal cord can be very serious, in extreme 
cases paralysis may occur [45].  With these factors in mind, MOSFET detectors for this 
plan were placed in the contra-lateral lung, the spinal cord, and the mediastinum. The 
DVH of this plan is shown in Figure 4.6 and an image of the plan including isodose 
lines is shown in Figure 3.7. 
 
This plan was designed to test the TPS’s ability to calculate the absorbed dose in the 
lung along with the use of wedges.  As shown in Figure 3.6, one of the beams exits 
through the spinal cord.  It was decided that MOSFETs would be placed in the spinal 
cord to compare the measured doses with those of the TPS’s.  The dose to the spinal 
cord is important to consider while creating a radiotherapy treatment plan as spinal 
cord toxicity can occur [45, 46].  This was decided to be a relevant part of the audit and 
the interest point doses in the spinal cord were collected for both treatment plans used 
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in the audit.  The exact location of the interest points for the clinical are demonstrated 
in Figure 3.6  
 
It was chosen to have a lung plan that would resemble those typically used in clinical 
cases.  This treatment plan consisted of two beams, which both used 60 degree 
wedges at gantry angles of 200 and 280 degrees and, like the mediastinum plan, uses 
6 MV photons.  These beams had a relative weighting of 0.48 and 0.55 to the dose 
prescription point respectively.  After consulting a clinical oncologist, Dr. Nik Nedev 
from Palmerston North Hospital, the proposed plan was slightly modified by increasing 
the field sizes from 4 cm by 4 cm to 5 cm by 5 cm which was considered to be more 
realistic.   
 
 
 
Figure 3.6  Clinical lung plan, using 5 by 5 cm fields with 60 degree wedges and 6 MV photons 
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Figure 3.7 The clinical lung plan with isodose lines 
 
 
3.4. Point doses and contouring 
The two plans that would be used for the audit were the parallel opposed mediastinum 
plan (also referred to as the simple plan) and the clinical lung plan.  The decision of 
where interest point doses were going to be measured within the phantom (where the 
MOSFETs were going to measure the dose) remained to be made.  After some 
cursory investigation it was decided that there would be two MOSFETs measuring the 
dose in the tumour volume for each of the plans.  This was because it was desired to 
establish an accurate measured dose in the tumour volumes [47] since the dose to 
the tumour volume was considered to be the dose of the most importance. 
 
Both plans also included measured doses in the spinal cord, as well as out of the 
primary beams.  These MOSFETs were there to make sure that the calculated dose 
to the spinal cord was correct.  MOSFET detectors were also placed within the 
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primary beams in places other than the spinal cord and the tumour volumes.  This 
was done to check that the exit and entry doses were calculated accurately by the 
TPS. The MOSFETs placed outside of the primary beams were there to measure the 
dose from the scatter of the beams.  This was done since some of the treatment 
planning algorithms underestimate scatter [10].  In total five MOSFET detectors were 
placed in the phantom for each plan (see Figure 3.8 Figure 3.9).  Six interest point 
doses were collected for each plan from the TPS in the centres.  This sixth interest 
point dose was the dose at the normalisation point which is in the centre of the tumour 
volume/insert5.  A TPS interest point dose for the normalisation point could not be 
verified with a MOSFET detector as the detectors cannot be placed at this point in the 
phantom.  However it was collected from the centres so a comparison of the dose to 
the prescription point calculated by the centres respective TPSs could be made.  It 
should be noted that the dose at the interest points in the tumour was very close to 
the prescribed dose in the normalisation point because the dose distribution in the 
tumour volume was fairly uniform.  
 
To be able to compare the doses of the TPS to the measured doses, the centres were 
asked to obtain interest point doses from their TPS for where the MOSFETs were to 
be placed.  This was carried out while the centres were creating the treatment plans.  
The accuracy of the radiotherapy treatment system of each particular centre was 
determined by comparing the interest points from the TPS to the doses measured by 
the MOSFETs after irradiation of the phantom. 
 
                                                 
5
 The tumour volume was defined to be part of the insert. 
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Figure 3.8 The point doses in the clinical lung plan marked by the blue crosses.   
 
 
 
 
Figure 3.9 The point doses in the mediastinum plan represented by the blue dots  
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Each centre placed the interest points in the TPS using the co-ordinates (with the co-
ordinate system specified in the audit protocol) that was provided in the audit protocol 
(Appendix A).  The interest points were then manually adjusted by precisely placing 
them visually, which was easily done since the MOSFET slots in the inserts were 
visible on the CT images in the TPSs.  These small adjustments from the co-ordinate 
points were necessary because some of the interest point doses were not exactly in 
the right locations (the right locations being in the exact centre of where the MOSFET 
detectors could be placed).  This was possibly due to slightly different positions of the 
phantom during the CT scans, as it is possible that the phantom was slightly skewed. 
The calculated dose to the interest points was then compared to the measured results 
by the MOSFETs. 
         
   Right         Left 
 
Figure 3.10 This figure shows the contouring that the centres were asked to carry out.   
 
The centres were also asked to contour certain structures in the phantom.  These 
structures were; the left lung, the right lung, the skin of the phantom, the treatment 
volumes, and the spinal cord.  The contoured structures and the labelling of the 
inserts are shown in Figure 3.10.  This information was gathered so that it was 
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possible to compare the DVHs.  This information is important because the integral 
dose to the organs can have implications on patient outcome; organ toxicity can occur 
if too much dose is given to too greater proportion of an organ [48]. 
 
 
3.5. Creation of the protocol 
The protocol was the list of instructions and information that the centres were to follow 
in order to participate in the audit.  These instructions had to be clear and easy to 
follow so as not to be a burden on the already busy centres. 
 
The protocol provides step by step instructions for obtaining the CT images of the 
phantom, creating the plans in the TPS (including interest point doses and 
contouring), and also the treatment of the phantom.  The audit protocol was read and 
edited by medical physicists and was also discussed with an RT in order to ensure the 
usefulness of the protocol.  The audit protocol was easy to follow for the participating 
centres and was detailed enough to gather meaningful information.  The detailed 
protocol is given in Appendix A.  The following section briefly addresses the individual 
steps. 
 
3.5.1 The CT parameters 
The CT parameters to be used were specified in the protocol.  The protocol states that 
the phantom should be scanned head first in the supine position with the use of 
standard reconstruction filters. 
 
The central (zero) slice was defined to be at the half way point of the phantom (Figure 
3.11).  This also is where the inserts end in the phantom as shown in Figure 3.11.  
The MOSFETs can only be placed in the + 1.5 cm slice in the phantom, because this 
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is the slice where the inserts have the slots for MOSFETs to be inserted.  This is  also 
the slice where all the interest points were placed, including the normalisation points 
and beam isocentres.  The portion of the phantom imaged was 8 cm superiorly and 
inferiorly of the CT origin. 
 
When the phantom was imaged, it was asked that the slice thickness would be 0.25 
cm.  If this was not possible the slice thickness was to be a devisor of 1.5 cm so that 
in the TPS there would be a slice at + 1.5 cm where the beams as well as the interest 
point doses could be placed.  This slice also contained the centre of the tumour 
volumes. 
 
Figure 3.11 The zero slice in the CIRS chest phantom and the location of the MOSFETs 
 
 
3.5.2 Treatment planning 
It was requested that an RT carry out the treatment planning because they generally 
do planning on a day to day basis and it was thus reasoned that they were more likely 
This line was defined to 
be the 0 slice in the 
phantom; this is also 
where the inserts end 
in the phantom 
This line shows 
1.5 cm, this is 
how far from the 
zero slice the 
MOSFETs can 
be placed in the 
inserts. 
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to do the planning more time efficiently, with less errors in the treatment planning 
parameters, and provide more accurate contouring.  However, for the preliminary 
audit run this was not always possible, and in these cases a medical physicist carried 
out the planning. 
 
For each of the plans in the audit, the reference point, normalisation point, and the 
isocentre, were all defined to be the same point in the phantom (each plan had a 
different normalisation point though, as the treatment volumes are in different parts of 
the phantom for the two plans).  The planned dose to these points for both the plans 
was 2 Gy.  This dose was chosen for three reasons; it was a realistic dose for a 
fractionated treatment, it was small enough to avoid expending the MOSFETs too 
quickly, and it was high enough that relatively accurate measurements could be taken 
with the MOSFETs.   
 
The beam parameters were all specified in the audit, namely, no multileaf collimators, 
shielding, compensator or bolus were to be used.  This was done so that a more 
effective comparison between the centres could be carried out, as the use of these 
techniques would add more variables to the audit, which would mean that there would 
also be more sources of potential error.   
 
After the placement of the interest points in the plans, the dose (in Gy) to these points 
is written into the tables that are at the end of the protocol (Appendix A).  The time 
that was taken for the treatment planning is also recorded on the same page as the 
tables with the interest point doses.  This data was collected so the extra work load 
that the centres undergo to partake in the audit could be ascertained.   
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3.5.3 Transferring of patient data 
Once the treatment planning was complete it was requested that the treatment plan 
data, with the contouring and the interest point doses, were exported in DICOM or 
RTOG format on to a CD so that the DVHs could be compared retrospectively 
between the centres. 
 
The audit protocol requests that all the data be transferred between devices in the 
usual manner.  The protocol asks that the CT information is sent to the TPS in the 
manner in which data is usually transferred while, more importantly, it also requests 
that the treatment plans are sent to the linac in the usual manner.  It was decided that 
it was not desirable that the linacs be set up completely manually.  This was so any 
potential sources in of error during the transit of information from the TPS to the linac 
could be discovered in this audit.  It also eliminates potential errors from the centre 
personnel typing in the incorrect monitor units or gantry angle that could occur with a 
medical physicist or RT entering the beam parameters manually. 
 
 
3.6. Discussion and summary 
The audit protocol was designed to encompass the ability to test various parameters 
of the radiotherapy treatment process.  The tumour volumes had to be decided on, the 
treatment plans had to be created, and decisions had to be reached concerning the 
location of the interest point doses and contouring.  Perhaps most importantly the 
treatment protocol had to written in a way that all the centres would find the 
participation in the audit an undemanding yet clearly useful experience. 
 
The tumour volumes were decided to be the last 3 cm of a phantom insert, as this is 
where the MOSFETs could be placed without alterations to the phantom.  All the 
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treatment plans were designed to deliver a dose of 2 Gy to the centre of the tumour.  
This point in the tumour was also the; prescription point, normalisation point and beam 
isocentre, as these were all defined to be at the same point. 
 
A treatment plan delivering to the mediastinum was created that consisted of two 
parallel opposed beams, and as it was simple, it would only test simple beam 
parameters.  The possibility of including a lung plan in the audit procedure was then 
considered so more complex beam parameters would be tested.  Any treatment plan 
in the lung also tests the TPSs ability to accurately calculate the dose with the 
inclusion of sharp patient density changes. 
 
To determine whether it was possible to include a treatment plan to the lung it had to 
be discovered whether the altered conditions of charged particle equilibrium would 
affect the accuracy of the readings of the MOSFET detectors.  This was done by 
means of two parallel opposed beams to a tumour volume in the lung.  Once it had 
been confirmed that the MOSFET detectors could indeed accurately measure the 
dose in the lung, it was decided to investigate the use of a more complex plan which 
would test more complicated beam parameters.   
 
The clinical lung plan consisted of two beams at 80 degrees to one another, with each 
beam using 60 degree wedges.  To ensure the clinical lung plan was indeed clinical, it 
was sent to a clinical oncologist who recommended that the field sizes be enlarged 
from 4 cm to 5 cm. 
 
The interest point doses in the audit practice run were chosen for the maximum 
efficacy of collecting relevant information about the delivered doses.  Contouring was 
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also included of the tumour volumes, the right lung, the spinal cord as well as the 
phantom, so DVHs could potentially be compared between the centres. 
 
Great care was taken to ensure that the audit protocol was easy to follow.  To do this 
a variety of hospital staff was consulted, and changes were made to the protocol as 
they were recommended.   
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4. Results and discussion 
The first half of this chapter gives the results and discusses the three main preliminary 
phantom measurements, which included the parallel opposed lung plan, carried out 
with both the tissue and lung insert, the mediastinum plan, which also consisted of 
parallel opposed beams, and the more complex lung plan.  Draft plans were initially 
used to help select which plans were going to be used for the main audit.  The clinical 
lung plan was also trialled at Christchurch hospital. 
 
The second half of the chapter gives the results of the audit practice runs at two New 
Zealand hospitals following the audit protocol developed in this project.  The only 
involvement that NRL and myself had during the audit practice runs was assembling 
the phantom and the detectors, while the hospital staff executed all the other steps.  At 
the conclusion of this section there is a general discussion about these first practice 
audit runs. 
 
4.1. Preliminary phantom measurements 
In all of these preliminary phantom measurements the phantom was set up manually 
under the linac in the treatment 2 bunker in the Christchurch hospital’s oncology 
department.  This linac is a Varian 21iX S/N 1009 model capable of delivering 6 and 18 
MV photon beam energies, with a Varis treatment console.  All the measurements 
were corrected for angular dependence and energy dependence according to Equation 
1 in section 2.6.1. 
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4.1.1 The mediastinum plan 
This plan was a parallel opposed beam plan with the tumour volume in the centre of 
the phantom.  The two beams are placed posteriorly and anteriorly.  This plan was 
made and carried out to test the MOSFETs in the phantom with no complications such 
as wedges or density changes to affect the dose deposited.  Two MOSFETs were 
placed in the tumour volume, one in the spinal cord tissue and two outside the beams.  
The interest point locations that were measured in this plan differ from those measured 
in the practice audit run (section 3.2.2).  The interest point locations used in the first 
run of the phantom with the mediastinum plan are shown in Figure 4.1 and the DVHs 
of the plan are shown in Figure 4.2.  The numbered point doses correlate with the 
location column in Table 10.  This table also includes the percentage difference 
between the TPS calculated dose and the measured. 
 
 
Figure 4.1 the mediastinum plan with the locations of the interest points that were measured in the 
first phantom run with the mediastinum plan. 
 
 
 
1 
2 
3 
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Table 10 the results from the parallel opposed mediastinum plan.  
MOSFET 
No. location 
Average 
of 
readings 
(mV) 
Relative 
std dev 
(%) 
measured 
dose (Gy 
TPS dose 
(Gy) 
% diff between 
TPS and 
measured 
2914 1 214 1.7% 1.96 1.999 1.8% 
2912 2 202.7 0.3% 2.02 2.0002 -1.1% 
2931 3 202.7 0.5% 2.12 2.096 -1.0% 
2933 4 11.7 13.1% 0.11 0.124 15.1% 
2933 5 4 25.0% 0.037 0.010 267% 
 
 
 
Figure 4.2 DVH of mediastinum plan. 
 
 
In all of the measured points in the mediastinum plan of around 2 Gy (interest points 
1-3), which include the two points in the tumour volume and in the spinal cord, there 
was a good correlation between the TPS calculated dose and the measured ones 
Patient 
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where the greatest difference in absolute dose was 0.04 Gy.  In places outside of the 
beams (points 4 and 5) the TPS doses underestimated the dose (though only by 0.01 
Gy at interest point 4).  In terms of absolute dose however it is small, with a dose 
difference of 0.03 and 0.02 Gy for points 4 and 5 respectively (see Table 10).  Since 
the MOSFETs showed a good linear response even at low doses (though the 
MOSFETs are comparatively noisy), it seems that the TPS is slightly underestimating 
these doses.  However, as the linearity measurements were performed with 60Co, it is 
possible that the linearity of the MOSFETs is poorer with the comparatively high dose 
rate of the linac.  Another possible cause for the large relative discrepancy between 
the TPS and the measurements is that some TPS algorithms do not calculate the 
dose beyond a certain distance from the edges of the field.  TPS algorithms can have 
limited accuracy near changes in tissue density, such as between lung and tissue, 
which could also explain the discrepancy between these doses.   
 
 
4.1.2 Parallel opposed lung plan 
This plan was to ascertain whether it was possible for the MOSFETs to read properly 
in the phantom’s lung tissue.  It was uncertain if there would be charged particle 
equilibrium in the tumour volume, with the density changes from the tissue to the lung 
tissue, and how this would affect the measurements with the MOSFETs.  Two beams 
placed posteriorly and anteriorly were used without wedges.  This plan was also 
repeated with a tissue insert in the lung and the results were compared. 
 
The numbered points which represent the locations of the interest points at which 
doses were measured and compared with the TPS are shown in Figure 4.3.  These 
marked interest points correlate with the location column in Table 7.  This also 
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compares the TPS doses with the measured doses. The DVH for this plan with the 
lung insert in the lung is shown in Figure 4.4. 
 
 
Figure 4.3 The points where the dose was measured in the parallel opposed lung beam are 
marked by the blue crosses and are also numbered.   
 
 
 
 
 
Table 11 the results from the parallel opposed lung plan with the lung insert.   
 
MOSFET 
No. location 
Average of 
readings 
(mV) 
 Relative 
std dev 
(%) 
measured 
dose (Gy) 
TPS 
dose 
(Gy) 
% diff between 
TPS and 
measured 
2914 1 212 1.2% 1.94 1.96 0.8% 
2912 2 209 1.3% 2.09 2.07 -0.9% 
2931 3 9.7 6.0% 0.090 0.064 -41.4% 
2933 4 4.7 12.4% 0.043 0.012 -257.6% 
 
1
2 
3 
4 
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Figure 4.4 The DVH of the parallel opposed lung plan.  The treatment volume in this case was 
PTV 1 
 
 
The measured doses in the tumour volume were well within the uncertainty of the 
MOSFETs.  The MOSFETs outside of the main beam however showed that the TPS 
doses outside of the main beam were relatively lower than the measured ones, 
suggesting that the TPS underestimated the dose from scatter.  
 
While the doses outside the main beams were underestimated by the TPS, in terms of 
absolute dose, it was very little in both cases; it was less than 0.03 Gy.  The 
MOSFETs are also less proportionally accurate at very low doses, this is what was 
found in the measurements performed in this project (Chapter 2) and is also reported 
by other researchers [49, 50]. 
 
The excellent results in the high does region obtained in this plan meant that a lung 
plan could be considered for the audit, as it meant that the MOSFETs could measure 
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the dose accurately in the lung.  Once this was established, which was also outlined in 
chapter 3, it was possible to consider a more complex lung plan. 
 
4.1.3 The clinical lung plan 
This was the plan that was designed to test more of the parameters of the treatment 
planning system, and was also used for the practice audit run.  Like the mediastinum 
plan, the measured doses were in different locations than those chosen for the audit 
run.  The clinical lung plan was also altered slightly between the preliminary phantom 
measurements and the practice audit runs.  The field sizes of the beams were 
extended from 4 cm by 4 cm to 5 cm by 5 cm.  The results for this plan are shown in 
Table 2 and Figure 1.1 shows the interest point locations used in these 
measurements. 
 
 
Figure 4.5 the numbered interest points where the doses were measured in the preliminary 
phantom measurements of the clinical lung plan.  The pink dots represent the locations of the 
measured doses, while the blue crosses represent the point dose measured for the preliminary 
audit run. 
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Table 12  The results from the clinical lung plan with the lung insert.  
MOSFET 
No. location 
Average of 
readings 
(mV) 
Relative 
std dev 
(%) 
measured 
dose (Gy) 
TPS 
dose 
(Gy) 
% diff between 
TPS and 
measured 
dose 
2914 1 211 2.2% 2.02 1.97 -2.6% 
2912 2 208 1.7% 1.99 1.96 -1.3% 
2950 3 216 0.1% 2.03 2.01 -1.1% 
2931 4 96 1.6% 0.86 0.92 5.9% 
2933 5 91 1.7% 0.88 0.87 -0.5% 
 
 
 
 
Figure 4.6 DVH of clinical lung plan.  
 
With the exception of MOSFET location number 4, the results in the preliminary 
phantom measurements of the clinical lung plan also showed that the doses to the 
interest points were accurate within the uncertainty of the MOSFETs. 
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At MOSFET location number 4 for this plan, the TPS dose and the measured dose 
differed by 0.06 Gy.  This could be due to several reasons.  One possible reason is 
that the interest point doses in the TPS were not entered at precisely the right 
location.  This would account for the difference as the dose gradient at this area was 
steep (though no steeper than at point 5), the isodose lines are shown in Figure 4.7.  
Another possibility is that the phantom was not set up precisely and with the steep 
dose gradient in this area, a small error in the position of the phantom could account 
for the discrepancy of the measured dose and the TPS dose.  
 
Figure 4.7 The Isodose lines for 50% of the dose to 35% of the dose, showing the dose gradient in 
the spinal cord. 
 
The results in Table 12 for the preliminary phantom measurements showed that the 
system that had been created with the MOSFET dosimetry system, the MOSFET 
commissioning (with the appropriate correction factors derived from this 
commissioning), and the phantom, could be used with confidence for the audit 
especially in the high dose regions.  The good results in all three of the preliminary 
phantom measurements showed that any large dose discrepancies could be found in 
Chapter 4 
 -73-  
the audit in the high dose interest point locations.  However, care has to be taken to 
ensure that the geometrical set-up is accurate before any conclusions can be drawn 
about any possible dose miscalculations of the TPS.  The dose discrepancies in low 
dose interest points also need to be treated with care as more information about the 
MOSFET response on standard sensitivity at low doses should be collected with high 
dose rates.  The current information and measurements on low doses with the 
MOSFETs means that these interest point locations can only be discussed in the most 
general terms [34]. 
 
4.2. The audit practice runs 
 
Two centres took part in the practice audit runs that will be referred to as Centre A 
and Centre B in this thesis.  This section will show the comparative interest point 
doses along with a discussion about the possible improvements of the both the 
protocol and the procedures of the audit personnel.  These practice audit runs were 
performed in conjunction with the NRL’s biennial audit of two of the centres in which 
they check compliance with New Zealand’s radiation regulations and the machine 
outputs.  The protocol was sent to the centres in advance so it could be read and any 
queries could be answered before the visit.  The ease in which the audit protocol 
(Appendix A) could be followed was an important element of the information gathered 
in these practice audit runs. 
 
The phantom and the MOSFET dosimetry system were transported without 
complication to both Centre A and Centre B in specially modified cases which 
transported the equipment unharmed.   
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4.2.1 Centre A 
Centre A was very busy on the days of the visit as it had been experiencing some 
problems with the linacs (mostly due to complications from power cuts), but all of this 
centre’s personnel were co-operative and helpful.  This centre had no problems 
following the audit protocol.  The scanning of the phantom went smoothly, with the 
exception of the minor detail of the slice thicknesses allowed by the CT scanner.  This 
centre could not have a slice thickness of 0.25 cm so it was then decided to use a 
slice thickness of 0.3 cm as this is a devisor 1.5 cm. (This means that there would be 
a slice at MOSFET locations, see section 3.5.1).   
 
The co-ordinate system that the TPS used at this centre (Pinnacle) labelled the axes 
differently than the co-ordinate system in the protocol, but this was quickly established 
and corrected for with minimal loss of time.  The interest point positions were 
corrected manually since some of the interest points did not lie precisely over the 
places where the detector could be placed.  The points were not systematically shifted 
however (they were not all off in the same direction).  This prompted the revision of 
the interest point co-ordinates in the protocol upon return to Christchurch. It was found 
that the phantom had been slightly skewed in the CT scanner in Christchurch. 
 
The initial planning at centre A took between 1 and 1½ hours and was carried out by a 
medical physicist.  This was done directly from the instructions of the protocol.  A 
large component of this time consisted of waiting for the TPS to calculate the doses to 
the interest points.  It was realised at this point that the dose grid size was not 
specified in the protocol, highlighting the need of the audit practice runs to show any 
inadequacies in the audit protocol.  Some further time was spent planning later on in 
the day, without the presence of any NRL personnel, as the linac that was booked for 
the audit was not the same linac as the treatment plans were originally made with.   
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An error was made by Centre A with their planning of the mediastinum plan.  The 
beam at 180 degrees did not have the correction factor to account for the beam 
passing through the couch applied.  This meant that there were not sufficient monitor 
units to give the prescribed dose to the tumour volume for this beam.  This shows that 
it would be more suitable for someone who plans regularly, normally an RT, to carry 
out the treatment planning as someone who plans regularly is less likely to make such 
a mistake that gives defective results for the audit.  This mistake also meant that, at 
first glance, the measured doses to the interest points were far too low, in one case by 
7% in the high dose region of the tumour volume.  This mistake did not affect the 
clinical lung plan as this plan did not require any of the beams to pass through the 
couch as the phantom had been placed with its base right to the edge of the couch. 
 
The exporting of the plan data from the TPS on to CD after the planning was also a 
slow process, mostly because it took some time to realise that the full plan data could 
only be transported in RTOG, not DICOM-RT format as the person exporting had 
limited experience in this procedure. 
 
The entire process of the treatment of the phantom, including setting up the phantom, 
the MOSFET detectors, and carrying out each of the two plans three times each, took 
slightly under two hours.  The offsets were applied by the medical physicists present.  
The treatments went without incident, with the small exception of a faulty MOSFET 
bias supply box (Figure 2.2, section 2.3) which was not recognising the presence of 
any MOSFET detector plugged into one of its five slots.  This bias supply was 
replaced before any irradiations of the phantom began, and all the MOSFETs were re-
calibrated upon return to Christchurch with the particular bias supply box that was 
used for the irradiations.   
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The results from the mediastinum plan 
Table 13 shows the comparison of the TPS doses and the measured doses for Centre 
A for the mediastinum plan.  These results do not give much constructive value as the 
correction factor of the couch was not applied in the treatment planning.  The point 
doses are shown in Figure 4.8.  
 
Figure 4.8 The location of the interest points in the mediastinum plan 
 
 
Table 13 The results from the mediastinum plan at centre A.  The percentage differences shown 
were calculated from the unrounded values. 
 
Mosfet 
No. location 
Average 
of 
readings 
(mV) 
Relative 
std dev 
(%) 
measured 
dose (Gy) 
TPS 
dose 
(Gy) 
% diff 
between 
TPS and 
measured 
dose 
% diff between TPS 
and measured 
dose with 
estimated couch 
correction factor 
applied 
2947 1 204.5 2.5% 1.85 1.99 6.9% 5.8% 
2950 2 213.8 1.7% 1.92 1.99 3.3% 2.2% 
2948 3 249.8 1.9% 2.21 2.28 3.1% 1.6% 
2933 4 5.8 8.7% 0.055 0.09 38% -- 
2931 5 1.3 76.6% 0.01 0.03 70% -- 
 
An estimated couch correction factor of 2% was applied for the beam passing through 
the couch in later analysis.  This showed that there was still a slight under dosing, 
though the MOSFETs at interest point locations two and three were within the 
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uncertainty of the MOSFETs.  The doses outside the main beam remained 
uncorrected for the couch because, in terms of absolute dose, the discrepancies were 
very small. 
 
 
The result from the clinical lung plan 
The measured values from the clinical lung plan correlated well with the TPS values at 
Centre A, as shown in Table 14, with the doses to the tumour volume well within the 
uncertainty of the MOSFETs.  In this plan at Centre A none of the beams passed 
through the couch to get to the phantom as the phantom was placed with the base at 
the very edge of the couch.  The interest point locations are shown in Figure 4.9. 
 
 
 
Figure 4.9 The locations of the interest points in the clinical lung plan 
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Table 14 The results from the clinical lung plan at centre A.  The percentage differences shown 
were calculated from the unrounded values. 
 
Mosfet 
No. location 
Average 
of 
readings 
(mV) 
Relative 
std dev 
(%) 
measured 
dose (Gy) 
TPS dose 
(Gy) 
% diff between 
TPS and 
measured dose 
2947 1 222.7 1.4% 2.02 1.97 2.3% 
2950 2 219.0 0.9% 1.99 1.98 0.6% 
2948 3 97.3 1.6% 0.89 0.86 3.6% 
2933 4 74.0 1.4% 0.68 0.72 -5.8% 
2931 5 5.3 21.7% 0.048 0.05 -3.4% 
 
4.2.2 The results from centre B 
Unlike Centre A, Centre B had a comparatively relaxed atmosphere with a seeming 
abundance of staff.  An RT had been delegated by the head of the medical physics 
department at this centre to do the treatment planning, but for reasons unknown a 
medical physicist carried out the planning instead.  The physicist did not want to read 
the protocol, but instead preferred verbal instructions.  This was unfortunate because 
the intention was to see how self-explanatory the audit protocol was. The original 
planning went quickly and was originally completed in under an hour.  Some of the 
interest points also had to be corrected manually at this centre too. 
 
Upon the first irradiation of the phantom, which was the first irradiation of the 
mediastinum plan, it was found that there was something not quite right with the 
delivered doses.  The dose delivered was less than ½ of the prescribed dose.  After 
some confusion, it was realised that medical physicist that did the planning did not 
prescribe the dose to the reference point in the tumour volume.  This error did not take 
long to fix in the treatment planning system, but it did take about half an hour to import 
the modified plan to the linac. 
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Once this had been completed, and the first set of good measurements had been 
taken with the mediastinum plan, the next plan (the clinical lung plan) was 
immediately loaded onto the linac.  As the physicists present had not read the protocol 
they did not realise that each plan had to be completed three times. 
 
There were more delays trying to get the mediastinum plan re-loaded into the 
machine.  Eventually it was decided to enter the beam parameters manually into the 
linac.  There were also some delays doing this, as the physicist entering the monitor 
units switched the monitor units for the two beams in one of the irradiations.  This was 
realised upon reading the MOSFETs after this irradiation, so this plan had to be 
performed yet again. 
 
The clinical lung plan was executed three times without any problems.  This centre 
used physical instead of virtual wedges as they thought that the word ‘wedges’, 
without explicitly saying virtual wedges, implied that physical wedges should be used.  
The use of physical wedges did take longer since at every beam change the wedges 
had to be moved manually. 
 
At some point in time well into the treatments of the phantom, it was realised by one of 
the medical physicists that the couch correction factor had not been applied in the 
treatment planning, which was why the doses recorded were much lower than the 
TPS doses.  Due to the wider couch used at Centre A than Centre B, this affected 
both the mediastinum plan and the clinical lung plan.  This further highlights that 
ideally an RT would perform the treatment planning for the audit, especially as the 
same mistake occurred at both centres with the medical physicists performing the 
planning.  Since this error was realised before the final irradiation of the phantom, the 
beam parameters with and without the couch corrections were printed out so the 
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corrections could be applied in later analysis to the results that were obtained at this 
centre.  With the setup and delays it took around three hours to treat the phantom. 
 
Centre B, while more relaxed than Centre A, did not seem to take the audit as 
seriously and thus there were a lot of errors, mostly due to their unwillingness to read 
the protocol.  It also highlights the fact that if the phantom were treated in the same 
way as a patient is treated, these mistakes would be less likely to occur, and if they 
did, a more meaningful audit could take place as this would draw attention to any 
errors in the treatment system of that particular centre. 
 
 
The results from the mediastinum plan 
These results were corrected for the couch factor after irradiations, which is why the 
TPS doses to the tumour volume are less than those in the preliminary phantom 
measurements and the TPS doses from Centre A.  All the measured values matched 
very well with the corrected TPS values as shown in Table 15. It is worth noting here 
that the results from the MOSFETs outside the main beam (locations 4 and 5) were as 
accurate as the MOSFETs could be considering that the MOSFET reader does not 
show decimal places and the irradiations were repeated three times only. 
 
Table 15 The results from the mediastinum plan at Centre B.  The percentage differences shown 
were calculated from the unrounded values. 
 
Mosfet 
No. location 
Average 
of 
readings 
(mV) 
%std dev measured dose (Gy) 
TPS dose 
(Gy) 
% diff between 
TPS and 
measured dose 
2947 1 213.7 0.7% 1.97 1.96869 0.2% 
2950 2 214.7 1.4% 1.96 1.9795 1.1% 
2948 3 256.7 2.3% 2.28 2.29087 0.4% 
2933 4 6.3 9.1% 0.06 0.04945 -17% 
2931 5 1.7 34% 0.014 0.016 11% 
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The results from the clinical lung plan 
The measured doses and the TPS doses were significantly different in the tumour 
volume since the difference between the TPS dose and the measured dose was 
larger than the uncertainty of the MOSFETs as shown in Table 16.  The lack of the 
couch correction factor in the treatment planning was corrected for after irradiation. 
 
Table 16 The results from the clinical lung plan at Centre B. The percentage differences shown 
were calculated from the unrounded values. 
 
Mosfet 
No. location 
Average 
of 
readings 
(mV) 
%std 
dev 
measured 
dose (Gy) 
TPS dose 
(Gy) 
% diff between 
TPS and 
measured dose 
2947 1 204.3 3.5% 1.87 2.00 6.3% 
2950 2 204.3 1.7% 1.87 1.93 3.1% 
2948 3 91.0 1.1% 0.85 0.83 -2.8% 
2933 4 71.7 3.5% 0.66 0.69 3.9% 
2931 5 5.0 0.0% 0.045 0.05 17.0% 
 
It is not believed that the dose discrepancies measured here are indicative of real 
patients receiving incorrect doses at this centre, but rather a symptom of the 
personnel in this centre being unwilling to read the audit protocol.  So many mistakes 
and miscommunications occurred that would not be surprising if some error had 
occurred amongst this plethora of errors that affected the delivered dose. 
 
4.3. Discussion 
The results from all the phantom measurements were promising, showing that a 
meaningful audit could take place with the equipment that was used in this project, 
and the audit would pick up any large dose discrepancies in the future.  It also showed 
that the MOSFET dosimetry system’s performance assessment was characterised to 
a degree that allowed any large discrepancies in high dose regions to be apparent.  
Discrepancies in low does regions can only be stated in general terms [51].  More 
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information on the linearity at low doses with high dose rates is needed.  The use of 
two bias supply boxes for the audit could also be considered.  This would mean that it 
would be possible to measure the doses with MOSFETs on both the standard and 
high sensitivity bias supply settings.  Other research has found that peripheral 
radiotherapy doses measured with MOSFETs on high sensitivity measured these 
doses with a relative standard deviation of only 1% [52]. 
 
The practice audit runs gave valuable information on what could be improved in the 
audit protocol.  A main point is that someone who performs patient planning on a 
regular basis, usually an RT, should perform the planning, which was asked in the 
protocol, as a lot of the mistakes made in the audit practice runs were due to 
inexperience with practical treatment planning.  This could also reduce the burden on 
the centres participating in the audit as it would require fewer man-hours to perform 
the planning.  This could also be improved if one person was assigned to perform all 
the steps in the protocol, as this would limit the errors due to miscommunications 
between personnel.  Though, if this was done any errors due to inter-personnel 
communication through the various stages of the treatment process would not be 
found and since human error constitutes a significant proportion of radiation accidents 
in radiotherapy, this may not a desirable option. 
 
Small adjustments needed to be made to the audit protocol after the audit practice 
runs, like fixing up the interest point co-ordinates, specifying virtual wedges, including 
information on dose grid size, and a reminder to include couch correction factors in 
the treatment planning.  The manner in which the uncertainties were calculated could 
also be expanded to encompass the uncertainty in the MOSFET positions.  This 
would enable the audit to collect more valid information at low dose levels.   
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It is judged that if the protocol is carried out by one person, or a well co-ordinated 
team, the total man-hours required from each centre to participate would be around 
three hours, which would be one hour for the CT scan and treatment planning and two 
for the treatment of the phantom. 
 
The use of real instead of virtual wedges by Centre B could be a reason for the 
discrepancies in the doses outside of the main beams.  This depends on how the 
wedges were commissioned in the centre. 
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5. Discussion and Conclusion 
 
The aim of this project was to create a procedure for the verification of doses in 
radiotherapy in the New Zealand hospitals that perform such treatments.  To do this 
the equipment that the NRL had purchased, the CIRS phantom and the MOSFET 
dosimetry system had to be investigated in terms of suitability for such a purpose.  
The audit protocol also had to be created.  This entailed much investigation and 
thought on what exactly this audit would be testing.  It also involved the input from 
many clinical staff such as RTs, medical physicists, and a clinical oncologist, to 
ensure that the protocol was testing parameters relevant to radiotherapy while still 
being easy to follow. 
 
The MOSFET detectors were found to be suitable for measuring the dose in relatively 
high dose areas, but as the measured dose in low dose areas was comparatively 
noisy more investigation of the characteristics of the MOSFETs at low doses is 
needed before any definitive statements about low dose regions can be made. 
 
These detectors also have to be calibrated individually as the calibration factors and 
angular dependence was determined to vary considerably from one MOSFET to 
another.  The combined uncertainty from the ‘noise’ of the MOSFETs and the 
correction factors was found to be 3% with a coverage factor of 2.  A more accurate 
uncertainty could be found if the uncertainty was calculated individually for each 
MOSFET, including the standard deviation of the three measurements of the 
MOSFETs in the treatment of the phantom in the audit. 
 
The CIRS phantom provided by the NRL was found to be suitable to conduct this type 
of audit.  Some small alterations had to be made to the phantom throughout the 
course of the project.  The lines for the lasers at the top of the phantom did not match 
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the ball bearings just under the surface of the exterior of the phantom.  The MOSFET 
cavities in the phantom inserts had to be enlarged as most of the MOSFETs would not 
fit. 
 
In the preliminary phantom measurements performed at Christchurch Hospital, the 
measured doses and the TPS doses correlated within the uncertainty of the 
MOSFETs in the high dose regions.  All of these measurements were within 2%, with 
the exception of one location point in the clinical lung plan that was still within the 3% 
uncertainty of the MOSFETs.  It was also determined that the MOSFETs could 
measure the dose accurately in the lung despite concerns about how the differing 
conditions of charged particle equilibrium could affect the measured dose.   
 
The audit practice runs gave valuable information about the audit procedure that had 
been created.  It demonstrated what worked well in the procedure, what did not, and 
what needed to be clarified in the protocol.  Both of the participating centres did not 
apply the couch correction factors in the treatment planning, so a clear instruction for 
this was included in the protocol.  The TPS doses, for this reason, had to be altered 
upon return to Christchurch, and in the case of Centre A the couch correction factor 
was estimated.   
 
Both centres had one plan in which the measured results matched the TPS results 
within the uncertainty of the MOSFETs, and one plan which did not.  The plan which 
performed well was different for each centre.  Centre A failed to apply to the couch 
correction factor which affected the mediastinum plan, while at Centre B the tumour 
volume in the clinical lung plan received less dose then the TPS calculated, even with 
the couch correction factors being applied upon return to Christchurch.   For Centre A 
an estimated couch correction factor was applied, but, except for one interest point 
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dose, the difference in the measured dose and the TPS dose was still larger than the 
uncertainty of the MOSFETs at 5.8%.  Because the couch factor was only estimated, 
it cannot be stated definitively if there were any real dose discrepancies at Centre A.  
For Centre B, the largest discrepancy, which was 6.3%, was for the clinical lung plan.  
Since so many things went amiss at this centre, especially while the treatment of the 
phantom was being performed, largely due to miscommunications and choosing not to 
read the audit protocol, it is unlikely that this discrepancy gives any real information 
about the treatment abilities of the centre.  However, it did give valuable information 
about how the audit process that had been developed could be improved. 
 
In the future this audit could be expanded to encompass more complicated 
procedures such as stereotactic or IMRT treatment as they become more common in 
New Zealand.  If the audit was expanded to encompass these treatments, the dose 
information collected would also need to be expanded to estimate the effects of 
uncertainty of the detector positions.  This could be done by the analysis of two 
dimensional dose planes at the regions of interest. 
 
This project provides the basis for an external audit of the whole treatment chain for 
radiotherapy.  It also showed that carrying out a meaningful audit is possible with only 
minimal burden to the busy centres.  The lessons learnt in the audit practice runs will 
enable the smooth operation of this audit in the future.  The NRL is currently 
scheduled to carry out the full official nationwide audit of the verification of the doses 
in radiotherapy using the procedures created in this project in late 2008 or early 2009.   
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Appendix A 
 
This is the audit protocol that was developed during the course of this project.  
Appendix A1 is  also part of the audit protocol. 
 
 
Audit protocol 
 
Introduction 
This project is NRL funded with the purpose of doing two-yearly level three dose 
audits of NZ Radiation therapy centres.  It is being done in conjunction with University 
of Canterbury. 
 
The project will be carried out using a chest phantom and a MOSFET dosimetry 
system provided by NRL. Two treatment plans will be carried out, one in the chest and 
the other more complex one in the lung. The plans have been designed to minimise 
work for the centres. Below is a brief overview of what is required of the centres: 
 
1. CT the phantom 
o Acquire CT 
o Transfer to TPS 
2. TPS 
o Import CT images 
o Place 6 interest points per plan –(These are outlined later) 
o Contour 5 structures –(also outlined below) 
o Create two treatment plans -(treatment plan parameters are all 
specified) 
o Enter point doses into table 
o Transfer plans to linac 
o Export plans to CD/DVD in DICOM-RT format 
3. Linac 
o Irradiate phantom (3 times for each plan) 
o Enter MOSFET readings into table (done by NRL staff) 
4. Further evaluation carried out at NRL  
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Required resources 
TPS requirements 
The treatment planning system should be capable of performing 3D dose calculation 
which account for variations in scatter in the presence of heterogeneities. 
 
The treatment planning system at each centre must be capable of exporting data in 
RTOG or DICOM-RT formats (DICOM-RT if possible).  A local physicist should 
ensure that this procedure can be performed at the centre before the visit.   
 
Radiotherapy Treatment Requirements 
Treatment should be delivered on a megavoltage linear accelerator which provides 
• Delivery of 6 MV photons 
• Beam modifications (virtual wedges - if virtual wedges are not possible please 
inform us) 
 
The phantom will be treated three times for each plan so adequate time for a treatment 
unit booking should be scheduled for the phantom in the afternoon on the day of the 
centre visit.  This could be arranged out of hours, either a physicist or an RT would 
need to be there to place and treat the phantom. 
 
The beam parameters are fixed so MLCs should not be used, even though this maybe 
standard practice.  This is so information of the treatment can be compared between 
the centres. No tweaking of any of the planning parameters is required!  If any of the 
parameters outlined in this protocol are not possible, please inform us. 
 
Detailed description of audit 
1. CT the phantom 
a. As each centre will CT the phantom, a 30-minute radiotherapy planning 
CT booking should be scheduled for the phantom at the beginning of 
the day of the visit.    
b. The phantom has inserts in which the MOSFET detectors are placed.  
There are ten inserts which have been labelled as follows: 
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           Right         Left 
 
Figure 5.1 This diagram shows illustrates the structures to be contoured.  It also shows the insert 
numbers 
c. The inserts can rotate and should be in the correct place as for the 
treatments.  The correct place is with the MOSFET slots to be at 12 
o’clock, 3, 6, and 9. (This will be done by the NRL) 
d. The slices of the phantom should fit together snugly and line up 
properly so the edges are straight. (This will be  done by NRL) 
e. Align the central markers of the CIRS phantom with the CT room 
lasers. Do not use the original lines on the top of the phantom!!  Use the 
line which has been scored on the phantom. Note that the orientation of 
the phantom is in the supine position and note the labels on the 
phantom. 
f. Scan parameters: 
i. Slices thickness: 0.25cm 
ii. Interval: 0.25cm 
iii. Orientation: head first, supine 
iv. Scan length is 8 cm in either direction of the CT origin going 
superior to inferior. 
v. Reconstruction standard (standard filters) 
g. Export CT to TPS 
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2. TPS 
a. Import into TPS.  The patient data should be entered into the system as 
follows 
i. Patient name: CIRSphantom 
ii. Patient id: NRLddmmyy 
iii. StudySet: Chest 
b. It does not matter in which order the points and the contouring are 
done, so where possible follow normal practice. 
c. Generate points (Plan 1)  
These points will be used to get TPS doses. The CT origin is in 
the centre of the phantom. (where the placements lasers cross).  At 
this point x, y, and z equal zero on our co-ordinate system.  There 
are ball bearings in the phantom which will help find the origin.  
In the table below the coordinates of the isocentre is also the 
normalisation point and the prescription point.  After the beams 
have been placed enter the point doses into the table. The dose 
grid size should be the usual size which is used.  If there is no 
standard grid size, use 3 mm.  Remember to include the couch 
correction factors! 
 
 Table of relative co-ordinate positions (Plan 1) 
Plan 1 Thoracic 
plan 
 
Point 
name x (cm) y (cm) z (cm) TPS Dose (Gy)  
Beam Isocentre and 
normalisation point T ISO 0 1.5 0  
        
interest point 1   T1 0.28 1.5 0.8  
interest point 2  T2 -0.97 1.5 0  
interest point 3  T3 -0.12 1.5 -6.61  
interest point 4  T4 -5.13 1.5 3.11  
interest point 5  T5 -8.98 1.5 0  
 
d. Generate points (plan 2) 
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Table of relative co-ordinate positions (plan 2) 
Plan 2 Clinical Lung Plan 
Point 
name x (cm) y (cm) z (cm) TPS Dose (Gy)  
Beam Isocentre and 
normalisation point L ISO -7.85 1.5 -4.58  
       
interest point 1   L1 -7.72 1.5 -3.54  
interest point 2  L2 -8.89 1.5 -4.58  
interest point 3  L3 -1.04 1.5 -5.5  
interest point 4  L4 -3.92 1.5 4.05  
interest point 5  L5 -1.04 1.5 2.95  
 
e. Enter interest point doses into table (after beams have been placed) 
f. Generate contours:  
i. External/patient 
ii. Lung left 
iii. Lung right 
iv. Spinal structure 
v. Only the tumour volumes outlined below need to be contoured 
no other volumes are required. 
vi. Tumour volume for plan 1:  
• The first 3 cm from insert six – from slice 0 to slice 12 ie, 
from y=0 to y=3 cm (figure 2 below) 
• This is 1.5cm either side of the normalisation point 
• To see the insert we recommend that window=800HU and 
Level = -100HU 
 
vii. Tumour volume for plan 2: 
• The first 3cm of insert eight – from slice 0 to slice 12 
• This is 1.5cm either side of the normalisation point 
• To see the insert we recommend that window= 200HU and   
Level = -800HU 
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Figure 5.2 This diagram illustrates the tumour volume.  It is this first three cm of the insert that 
should be contoured 
 
 
Treatment techniques 
In both plans the reference point and normalisation point and the isocentre are at the 
same point and the dose to be delivered to those points is 2 Gy.  The criteria below 
should not be altered as we do not want to test the planning ability of the centres, but 
rather that the TPS and the detectors are in agreement of the dose.  Also make sure that 
the plans have gone through the appropriate verification process and the plans are 
ready to use on the linacs when its time to treat the phantom.   
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Plan one – chest plan 
Mandatory Technique  Requirements 
Field Anterior Posterior 
Density Correction yes yes 
Isocentric Yes Yes  
Modality Photons Photons 
Collimators (cm) 5.0 by 5.0 symmetric 5 by 5 symmetric 
Gantry 0o 180o 
Collimator  0o 0o 
Couch 0o 0o 
Shielding No No 
Compensator No  No  
Bolus No  No  
Recommended Technique requirements 
Energy (MV) 6 MV 6 MV 
Wedge None  None 
Relative Weight 45 55 
Additional information 
SSD (CM) 90.9 89.0 
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Plan 2 – Clinical lung plan 
Mandatory Technique  Requirements 
Field 1 2 
Density 
Correction 
yes yes 
Isocentric yes yes 
Modality photons photons 
Collimators (cm) 5 by 5 symmetric 5 by 5 symmetric 
Gantry* 200 280 
Collimator 0 0 
Couch 0 0 
Shielding No  No  
Compensator No  No  
Bolus No  No  
Recommended Technique requirements 
Energy (MV) 6 6 
Wedge 60 o Thick end lat 60 o Thick end post 
Relative Weight 
at reference point 
48 52 
Additional information 
SSD (CM) 95.3 93.4 
* In the direction as defined by the IEC  
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Appendix A1 
What the centres need to do. . . . . 
1. CT the phantom. 
2. The treatment planning (with the CT data), which includes adding beams 
contours and point doses. 
3. Enter Point doses from TPS into the table provided. (The table is on the next 
page) 
4. Have the treatment plans ready for treatment i.e., has gone through the 
verification process and the plans are ready on the machine in time for 
treatment.  
5. Place the phantom for treatment. 
6. Export the treatment plans (including structure, dose and images) in DICOM-
RT format on to a CD/DVD. 
 
 
What NRL will do. . . . 
1. Put the phantom together ready for treatment with the inserts in the correct 
locations 
2. Arrange inserts with detectors in the correct location for treatment. 
3. Take the measurement readings from the irradiations 
4. Analyse the results obtained from the information gathered. 
5. Inform each centre of their own results 
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Tables of point doses to fill 
 
Table of relative co-ordinate positions (Plan 1) 
Plan 1 Thoracic 
plan  
Point 
name 
x 
(cm) 
y 
(cm) 
z 
(cm) 
TPS Dose 
(Gy)  
Fill this 
column 
Beam Isocentre and 
normalisation point T ISO 0 1.5 0  
        
interest point 1   T1 0.28 1.5 0.8  
interest point 2  T2 -0.97 1.5 0  
interest point 3  T3 -0.12 1.5 -6.61  
interest point 4  T4 -5.13 1.5 3.11  
interest point 5  T5 -8.98 1.5 0  
 
Table of relative co-ordinate positions (plan 2) 
Plan 2 Clinical Lung 
Plan 
Point 
name 
x 
(cm) 
y 
(cm) 
z 
(cm) 
TPS Dose 
(Gy)  
Fill this 
column 
Beam isocentre and 
normalisation point L ISO -7.85 1.5 -4.58  
        
interest point 1   L1 -7.72 1.5 -3.54  
interest point 2  L2 -8.89 1.5 -4.58  
interest point 3  L3 -1.04 1.5 -5.5  
interest point 4  L4 -3.92 1.5 4.05  
interest point 5  L5 -1.04 1.5 2.95  
 
 Also please give the following information 
 How long did the planning take: _____________________ 
TPS vendor, software and version used: _____________________________________ 
Calculation planning algorithm used: _______________________________________
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Appendix B  
 
MOSFET work sheet 
This is an example of a filled work sheet from one of the centres, it corrects for energy and 
angular dependence and calculates the corrected dose for all five points at the end of the 
sheet. There is two worksheets, one for the chest plan and one for the lung. 
 
chest plan        
        
Beam 1 parameters 
      
Gantry angle 0 degrees      
Monitor units 154 MU      
Beam energy 6 MV       
        
Beam 2 parameters 
      
Gantry angle 180 degrees      
Monitor units 2 MU      
Beam energy 6 MV       
        
        
Mosfet  data 
       
Mosfet 
number 
Cal factor 
(Gy/mV) 
Insert 
position Mosfet position    
2947 0.008837578 LC T       
2950 0.00892867 LC R       
2948 0.008838188 S L       
2933 0.009152487 CR R      
2931 0.009019833 RLT R      
             
Measurement readings: 
      
Mosfet 
number reading 1 reading 2 reading 3 reading 4 
beam 1 
weight beam 2 weight 
2947 203 199 211 205 0.45 0.55  
2950 213 212 211 219 0.45 0.55  
2948 254 248 244 253 0.1 0.9  
2933 6 6 6 5 0.5 0.5  
2931 0 1 2 2 0.5 0.5  
        
Mosfet corrections for beam 1 
     
Mosfet 
number angle mod angle 
angle 
correction energy weight Partial dose  
2947 270 90 1.05926 0.99 0.45 0.80448914 Gy 
2950 0 0 1 0.99 0.45 0.84327719 Gy 
2948 180 180 1.01855 0.99 0.1 0.21757852 Gy 
2933 0 0 1 0.99 0.5 0.02718289 Gy 
2931 0 0 1 0.99 0.5 0.00446482 Gy 
         
Mosfet corrections for beam 2 
      
Mosfet 
number angle mod angle 
angle 
correction energy weight Partial dose  
2947 90 90 1.05926 0.99 0.55 1.04153365 Gy 
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2950 180 180 1.01855 0.99 0.55 1.04978674 Gy 
2948 0 0 1 0.99 0.9 1.95820665 Gy 
2933 180 180 1 0.99 0.5 0.02718289 Gy 
2931 180 180 1 0.99 0.5 0.00446482 Gy 
        
Mosfet Corrected doses 
      
Mosfet 
number Dose       
2947 1.846022784 Gy      
2950 1.893063935 Gy      
2948 2.175785164 Gy      
2933 0.05436577 Gy      
2931 0.008929634 Gy      
 
 
Clinical Lung plan (2 oblique fields with dynamic wedges)    
        
Beam 1 parameters 
      
Gantry 
angle 200 degrees      
Monitor 
units 154 MU      
Beam 
energy 6 MV       
        
Beam 2 parameters 
      
Gantry 
angle 280 degress      
Monitor 
units 2 MU      
Beam 
energy 6 MV       
        
Mosfet  
data 
       
Mosfet 
number Cal factor (Gy/mV) 
Insert 
position Mosfet position    
2947 0.008837578 RLL R       
2950 0.00892867 RLL T       
2948 0.008838188 S R       
2933 0.009152487 RC T      
2931 0.009019833 S R      
             
Measurement readings: 
      
Mosfet 
number reading 1 
reading 
2 reading 3 reading 4 beam 1 weight beam 2 weight 
2947 219 224 225   0.48 0.52  
2950 217 221 219   0.48 0.52  
2948 96 97 99   0 1  
2933 73 74 75   1 0  
2931 6 6 4   0.5 0.5  
        
Mosfet corrections for beam 1 
      
Mosfet 
number angle 
mod 
angle 
angle 
correction energy weight Partial dose 
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2947 200 160 1.035271 0.99 0.48 0.935115 Gy 
2950 110 110 1.059262 0.99 0.48 0.929196 Gy 
2948 200 160 1.035271 0.99 0 0 Gy 
2933 110 110 1.059262 0.99 1 0.670511 Gy 
2931 200 160 1 0.99 0.5 0.023812 Gy 
         
Mosfet corrections for beam 2 
       
Mosfet 
number angle 
mod 
angle 
angle 
correction energy weight 
Partial 
dose  
2947 280 80 1.057063 0.99 0.52 1.070848 Gy 
2950 190 170 1.027244 0.99 0.52 1.034053 Gy 
2948 280 80 1.057063 0.99 1 0.900245 Gy 
2933 190 170 1.027244 0.99 0 0 Gy 
2931 280 80 1 0.99 0.5 0.023812 Gy 
        
Mosfet Corrected doses 
      
Mosfet 
number Dose  TPS dose diff % diff   
2947 2.005962531 Gy 1.97 0.035963 1.7928%   
2950 1.963249242 Gy 1.98 -0.01675 -0.8532%   
2948 0.900245139 Gy 0.86 0.040245 4.4705%   
2933 0.670511164 Gy 0.72 -0.04949 -7.3808%   
2931 0.047624717 Gy 0.05 -0.00238 -4.9875%   
 
